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A B S T R A C T
Background
The proportion of people living with and surviving cancer is growing. This has led to increased awareness of the importance of quality
of life, including sexual function, in those affected by cancer. Sexual dysfunction is a potential long-term complication of many cancer
treatments. This includes treatments that have a direct impact on the pelvic area and genitals, and also treatments that have a more
generalised (systemic) impact on sexual function.
This is an update of the original Cochrane review published in Issue 4, 2007, on interventions for treating sexual dysfunction following
treatments for cancer for men and women. Since publication in 2007, there has been an increase in the number of trials for both men
and women and this current review critiques only those for women. A review in press will present those for men.
Objectives
To evaluate the effectiveness of interventions for treating sexual dysfunction in women following treatments for cancer. To assess adverse
events associated with interventions.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 9), MEDLINE, EMBASE, PsycINFO,
AMED, CINAHL, Dissertation Abstracts and the NHS Research Register. The searches were originally run in January 2007 and we
updated these to September 2015.
Selection criteria
We included randomised controlled trials (RCTs) that assessed the effectiveness of a treatment for sexual dysfunction. The trial
participants were women who had developed sexual dysfunction as a consequence of a cancer treatment. We sought evaluations of
interventions that were pharmaceutical, mechanical, psychotherapeutic, complementary or that involved physical exercise.
Data collection and analysis
Two review authors independently extracted the data and assessed trial quality. We considered meta-analysis for trials with comparable
key characteristics.
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Main results
Since the original version of this review we have identified 11 new studies in women. The one study identified in the earlier version of
this review was excluded in this update as it did not meet our narrower inclusion criteria to include only interventions for the treatment,
not prevention, of sexual dysfunction.
In total 1509 female participants were randomised across 11 trials. All trials explored interventions following treatment either for
gynaecological or breast cancer. Eight trials evaluated a psychotherapeutic or psycho-educational intervention. Two trials evaluated
a pharmaceutical intervention and one pelvic floor exercises. All involved heterosexual women. Eight studies were at a high risk of
bias as they involved a sample of fewer than 50 participants per trial arm. The trials varied not only in intervention content but in
outcome measurements, thereby restricting combined analysis. In the trials evaluating a psychotherapeutic intervention the effect on
sexual dysfunction was mixed; in three trials benefit was found for some measures of sexual function and in five trials no benefit was
found. Evidence from the other three trials, two on different pharmaceutical applications and one on exercise, differed and was limited
by small sample sizes. Only the trial of a pH-balanced vaginal gel found significant improvements in sexual function. The trials of
pharmaceutical interventions measured harm: neither reported any. Only one psychological intervention trial reported that no harm
occurred because of the intervention; the other trials of psychological support did not measure harm.
Authors’ conclusions
Since the last version of this review, the new studies do not provide clear information on the impact of interventions for sexual
dysfunction following treatments for cancer in women. The sexual dysfunction interventions in this review are not representative of
the range that is available for women, or of the wider range of cancers in which treatments are known to increase the risk of sexual
problems. Further evaluations are needed.
P L A I N L A N G U A G E S U M M A R Y
Interventions for sexual dysfunction following treatments for cancer
Background
In women sexual dysfunction is a potential complication of many types of cancer treatments.
This review evaluated the effectiveness of treatments (interventions) of any kind, for example drugs or exercise, for treating sexual
dysfunction in women following cancer treatment.
The review is an update of one published in 2007 that assessed the effectiveness of interventions for men and women. We decided to
present this revised review separately for women because of the increase in the number of trials. Another review for men is underway.
Study characteristics
We identified 11 new trials on interventions for women in September 2015.We excluded one trial that was included in the earlier version
of this review because it assessed treatment for preventing sexual dysfunction and was no longer relevant to this review. Interventions
differed in their content and how the researchers measured benefit. Eight of the interventions involved psychological support such as
counselling on sexual matters, or peer support. One of the others was of a testosterone cream, another tested a vaginal pH-balanced gel
and the other was of pelvic floor exercise. The findings from six of the trials are weak because they involved small numbers of women.
Key results
Across the trials the impact on sexual function was different. This makes it difficult to derive clear conclusions. For instance, in those
that evaluated a psychological support treatment, four studies found that it improved some measures of sexual function but not others,
but five found that it did not improve sexual function according to any of the measures used. For the other interventions tested, only
the trial of the vaginal gel found improvements in sexual function and no side effects were reported. Only one of the psychological
interventions reported that no harm occurred because of the intervention. The other trials of psychological support did not assess harm.
This is an important gap as some women may find it distressing to discuss personal sexual problems as part of their treatment.
Further evaluations are needed for all interventions. Current studies have only explored effectiveness in women with gynaecological
and breast cancers, but there is a risk of sexual problems after treatments for other cancers. New evaluations need to involve larger
numbers of participants.
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B A C K G R O U N D
This review is an update of a previously published review in the
Cochrane Database of Systematic Reviews (Issue 4, 2007) on ’In-
terventions for sexual dysfunction following treatments for cancer’
(Miles 2007). This review presents the findings on the effective-
ness and safety of interventions for sexual dysfunction in women
following treatments for cancer. In its earlier version the review
involved interventions for both men and women following treat-
ments for cancer, and preventative treatments for sexual dysfunc-
tion. A separate review, in press, will report on interventions for
men. Interventions for the prevention of sexual dysfunction are
not included in either of these reviews.
Description of the condition
Sexual dysfunctions are characterised by a disturbance in sexual
desire and in the psychological and physiological changes that
characterise the sexual response (Diagnostic and StatisticalManual
of Mental Disorders 5th edition (DSM-5) (DSM-5 2013)).
The DSM-5 recognises three sexual dysfunctions in women:
• sexual interest/arousal disorder;
• genitopelvic pain/penetration disorder;
• female orgasmic disorder.
Sexual dysfunction poses challenges to one’s social, mental, emo-
tional and physical wellbeing. In cancer, it is an important indi-
cator of quality of life both in people undergoing treatments and
in those surviving the disease (Ozyilkan 1995). It may occur as a
result of the nature of a cancer, such as a cancer that affects the
mechanics or hormonal pathways in sexual function, as a result of
the treatment for cancer such as surgery, chemotherapy or radio-
therapy that may have local or systemic and hormonal effects, and
it may occur from the emotional trauma of receiving a diagnosis or
indeed living with cancer for the patient as well as their sexual part-
ner. The causes of sexual dysfunction following cancer treatments
may be multi-factorial but it may often result from the direct ef-
fects of the treatment. A hysterectomy, for example, may disrupt
the pelvic anatomy and the local nerve supplying the pelvic floor,
which are part of the trunk stability mechanism involved in sexual
arousal, and this may be accompanied by loss of vaginal lubrica-
tion and sensation (Jackson 2006). Other cancer treatments may
affect sexual function, for example chemotherapy may induce the
symptoms ofmenopause, in particular vaginal dryness. Sexual dys-
function following a cancer treatment may also relate to lowered
physical fitness, symptoms of depression or anxiety, and changes
to self esteem and feelings of sexuality (Greenwald 2008; Pignata
2001; Stead 2007; Tabano 2002; Wiggins 2008). Although some
treatment-related sexual dysfunction effects are short-term, sex-
ual dysfunction is one of the more prevalent long-term complica-
tions followingmany types of life-saving cancer treatment (Ananth
2003; Ganz 1998; Syrjala 1998).
Sexual dysfunction following cancer treatments is becoming an
increasingly important issue to tackle. With an aging global pop-
ulation, improved diagnosis and better cancer treatments, more
people are living with and surviving cancer. For example, the US
Centers for Disease Control and Prevention estimated that the
number of cancer survivors in the US increased from 3 million in
1971 to 11.6 million in 2007, and of those in 2007 the largest
group of survivors in women was those with breast cancer (CDC
2011). Sexual dysfunction is a knownproblem for people receiving
various cancer treatments, including those for cancer of the blad-
der (Bhatt 2006; Zippe 2004), head and neck (Low 2009; Singer
2008), and rectum (Hendren 2005; Ho 2011). However, much
of the research to date on the prevalence and treatments for sex-
ual dysfunction following cancer treatments has focused on cancer
treatments that have a direct impact on the genitals or other areas of
the body involved in sexual functioning. It has been estimated that
50% of women who undergo gynaecological cancer treatments
suffer long-term sexual dysfunction as a result (National Cancer
Institute 2012). There is also evidence for a high prevalence of
sexual dysfunction following treatments for breast cancer, where
in one survey it was found in 45% women (Kedde 2013), and in
another survey 76% had sexual dysfunction (Goldfarb 2009). A
review found that the incidence of sexual dysfunction in women
following radical rectal cancer resection varied from 19% to 62%
(Cowan 2013).
Despite recognition of the problem, sexual morbidity remains un-
der-treated in this patient group (Hill 2011). This is, in part, be-
cause of the embarrassment associated with sexual dysfunction not
only from the patient’s point-of-view but from that of clinicians
(Dening 2013). In addition, sexual interest/arousal disorders in
general may be under-recognised (Montgomery 2008).
Description of the intervention
There are various types of interventions available for the treatment
of sexual dysfunction in women, these include:
• complementary and alternative medicine interventions such
as the herbal therapies ginkgo and ginseng;
• exercises to strengthen the pelvic floor;
• mechanical interventions such as lubricating gels and
clitoral therapy devices;
• pharmacological interventions including hormonal
therapies such as testosterone or oestrogen (these may be applied
topically or taken orally);
• psychotherapeutic and psycho-educational interventions
such as counselling or psychotherapy, which aim to reduce the
sexual dysfunction as well as improve the patient’s
communication skills with their sexual partner.
Psychotherapeutic interventions may be combined with
education to facilitate an understanding of treatment and it
effects.
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The range of interventions is in part explained by the range of
causes of sexual dysfunction, but also because it is known that the
appropriateness, effectiveness and suitability of each intervention
vary between individual patients.
How the intervention might work
The various types of interventions work in different as well as com-
plex ways, with some mechanisms of action poorly understood.
We briefly consider the mechanisms of action according to the
following groupings.
Complementary and alternative medicine
There are various complementary and alternative medicines that
are used to try to enhance sexual function. Their mechanisms of
action are often unknown. Maca is an Andean plant belonging
to the mustard family and it has been used for centuries to en-
hance fertility (Shin 2010).Maca is also reported to improve sexual
function in healthy human populations (Gonzales 2003). Ginkgo
biloba has been evaluated for depression-induced sexual dysfunc-
tion (Cohen 1998).
Exercises to strengthen the pelvic floor
Pelvic floor muscles give structural support to the pelvic organs
(urethra, vagina and rectum). Pelvic floor dysfunction may be a
direct outcome of gynaecological cancers and various cancer treat-
ments. For example, radical hysterectomy and radiotherapy of the
pelvic area may disrupt the anatomy and the local nerve supply
to the pelvic floor muscles (Jackson 2006). This disruption may
lead to urinary continence and a lack of sexual arousal. Pelvic floor
exercises may reduce these problems by increasing muscle tone.
Mechanical
There are various mechanical devices for sexual dysfunction. In
women a clitoral therapy device such as a hand-held battery pow-
ered vacuum creates a gentle suction to engorge the clitoris blood
flow and thereby increase sensation (Schroder 2005).
Pharmacological
The relationship between endogenous testosterone levels and sex-
ual function in women has not been clearly established. How-
ever, testosterone therapy has been found to improve the signs and
symptoms of hypoactive sexual desire (Hubayter 2008). Exoge-
nous oestrogen will increase vaginal blood flow and lubrication,
and oestrogen therapy has been shown to improve clitoral sensi-
tivity and the ability to reach orgasm (Berman 1999).
Psychotherapeutic and psycho-educational
Although evidence for the effectiveness of psychotherapeutic in-
terventions is limited, the role of psychological processes in sexual
function is acknowledged (Kazdin 2009). Normal sexual function
is a biopsychosocial process that relies on the co-ordination of not
only endocrine, vascular and neurological factors but also psycho-
logical factors (Allahdadi 2009). Treatment of sexual dysfunction
in women with a psychotherapeutic intervention is a common ap-
proach in clinical practice (Berner 2012). There are a number of
psychotherapy approaches including cognitive behaviour therapy,
counselling and relationship therapy. Some interventions may in-
clude educational aspects, such as a discussion on the value of in-
timate communication with sexual partner and advice on vaginal
lubrication.
Why it is important to do this review
Trials evaluating the effectiveness of treatments for sexual dysfunc-
tion often exclude patients with other major health problems, such
as cancer. As cancer and its treatments disrupt physiological and
anatomical integrity, it is not possible to simply extrapolate the
results of these trials into the cancer field.
With the world’s aging population, and improved diagnosis and
better cancer treatments,more people are livingwith and surviving
cancer. It is recognised that sexual morbidity is a major cause of
poor quality of life. A growing number of treatments are being
developed and evaluated; it is important to review their efficacy,
safety and acceptability. This review is an update of an earlier
Cochrane reviewon interventions for sexual dysfunction following
treatments for cancer in men and women (Miles 2007). Since its
publicationmanymore trials have been undertaken. In light of this
growth we have split this review. In this current update we evaluate
only interventions for women. The update on interventions for
men will be reported elsewhere in a new review.
O B J E C T I V E S
• To evaluate the effectiveness of interventions for treating
sexual dysfunction in women following treatments for cancer.
• To assess adverse events associated with interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We only included randomised controlled trials (RCTs). Published
trials that were provided in full rather than in abstract only (such
as a conference abstract) were eligible. There was no language
restriction. In the case of cross-over trials, we only reported the first
period results (if available) in this review in order to exclude any
carry-over effect. Trials undertaken in any care setting, including
hospital and community, were eligible.
Types of participants
Trial participants were women (aged 16 years or over), receiving
any active treatment for any cancer or who had previously received
any treatment for cancer. Participants must have been functioning
sexually with a partner prior to cancer treatment. Participants at
the start of the trial needed to have experienced any type of sexual
dysfunction (however identified) subsequent to cancer treatment.
If participants were not required for trial inclusion to have sexual
dysfunction subsequent to cancer treatment, we included the study
if it reported:
• 50% or more having sexual dysfunction following
treatment;
• subgroup analysis on those with documented sexual
dysfunction subsequent to cancer treatment;
• mean/average score in both trial arms at early measurement
post-treatment indicating a level of sexual dysfunction.
We did not use theDSM-5 criterion that the duration of the sexual
dysfunction had to be at least six months.We felt that this may not
be relevant in this patient group as a significant proportion may
have advanced disease with a prognosis of less than six months.
Types of interventions
We included evaluations of any type of intervention for treating
sexual dysfunction following a treatment for cancer. These in-
cluded pharmacological, mechanical, psychotherapeutic and psy-
cho-educational, complementary medicine or exercise. The inter-
vention for sexual dysfunction could be compared with a placebo,
usual care or another active treatment.
We did not include trials of preventative strategies to refine the
cancer treatment, such as peritoneal vaginoplasty in combination
with a radical hysterectomy.
For this update, we only included studies of interventions for the
treatment of sexual dysfunction in women, not the prevention of
sexual dysfunction.
Types of outcome measures
Primary outcomes
The primary outcomes of interest were efficacy in regards to im-
proved sexual function, quality of life and safety. We evaluated
efficacy using the following outcomes:
• the proportion of participants within each trial arm with
improved sexual function;
• mean scores on standardised sexual function questionnaires;
these included the Female Sexual Function Index (FSFI), which
involves 19 items yielding an overall sexual function score in
addition to subscale scores for sexual desire, arousal, lubrication,
orgasm and satisfaction (Rosen 2000);
• mean scores on standardised quality of life measures
including the Quality of Marriage Index, which involves six
items of marital quality (Norton 1983).
We evaluated safety using the following outcomes:
• number and type of adverse effects;
• number of participants who dropped out due to adverse
effects.
Secondary outcomes
The secondary outcomes of interest were efficacy in regards to
psychological and physiological functioning, and symptoms of
disease.
We reported measured outcomes on sexual dysfunction relating
to the patient’s sexual partner.
Exclusion criteria
We did not include data from observational cohort or cross-sec-
tional studies, nor RCTs evaluating the effectiveness of preven-
tative measures such as breast reconstruction, or avoidance of
one particular therapy. We did not include studies comprising of
healthy volunteers or patients who reported sexual dysfunction
subsequent to non-cancer treatments.
Search methods for identification of studies
Electronic searches
In the original review we searched for interventions for both men
and women (Miles 2007). In this review we also planned to review
interventions for both men and women. It was the high number
of relevant studies found from these update searches which led
us, to permit timely completion, to split the review into one on
interventions for sexual dysfunction following treatments for can-
cer in women, and one on interventions for sexual dysfunction
following treatments for cancer in men.
We searched the following electronic databases irrespective of lan-
guage and publication status for the 2015 update:
• Cochrane Central Register of Controlled Trials
(CENTRAL 2015, Issue 9);
• MEDLINE (1966 to August 2015);
• EMBASE (1980 to September 2015);
• PsycINFO (1966 to September 2015);
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• AMED (1985 to August 2015);
• CINAHL (1966 to September 2015);
• National Health Service Research Register (containing the
Medical Research Council Directory) (1990 to January 2007);
• metaRegister of controlled trials (mRCT) (www.controlled-
trials.com/mrct), ClinicalTrials.gov (www.clinicaltrials.gov) and
the World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (http://apps.who.int/
trialsearch/) to September 2015.
Please see Appendix 1 for search strategies.
Searching other resources
We checked for further relevant trials via the reference lists and
undertook forward citation tracking for included trials. We also
checked for further relevant trials via the reference lists of any
related reviews.
Data collection and analysis
Two authors (BC, LJ) screened the keywords and abstracts of elec-
tronic citations. Where they appeared to be relevant, we obtained
the full texts.
Selection of studies
Following screening, two review authors (BC, LJ) assessed the full
text of potentially eligible citations for inclusion. If differences of
opinion had arisenwe planned to discuss this with the other review
authors (VV,MK and AT) and if resolution had been difficult, we
planned to attempt to contact the study authors for clarification.
We documented studies excluded after full-text assessment, giving
reasons for exclusion.
Data extraction and management
Wedesigned a data extraction form for this review.Where possible,
we extracted the following information for each trial.
• Methods: trial design, duration, allocation method,
masking and care setting.
• Aim and inclusion criteria.
• The number of patients eligible, the number randomised
and reasons why any patients were not included in the trial.
• The number of participants evaluated at follow-up(s),
reasons for loss to follow-up and how the trials, if stated, handled
deviations from randomised allocation and missing response.
• Participant characteristics: their age, gender, cancer and
treatment, and measure of sexual function at baseline.
• Content of the intervention including who delivered it,
duration and number of sessions and the mode of delivery
(including whether it was conducted with individuals or in a
group setting). We also report whether the content of the
intervention was standardised by the use of a manual.
• Comparison intervention including content, duration and
mode of delivery.
• Outcome data at the end of treatment and at the end of
follow-up, including how it was measured. We extracted details
on all outcomes on which authors collected measurements but
only provide details in our results of those relevant to this review,
specifically on sexual function, quality of life and safety, and of
psychological and physiological functioning and symptoms of
disease. We extracted, as appropriate, all outcome data on our
outcomes of interest if they were reported in the trial papers.
These included baseline scores, change scores and scores at
follow-up between the trial arms.
• We also planned to extract any qualitative evidence in the
included studies, such as analysis of participants’ views on the
value of the intervention.
Where information was lacking, we attempted to contact the trial
authors or trial sponsors.
Two review authors (BC/VV) independently extracted data. One
author (BC) entered the extracted data into ReviewManager 2014
and a second author checked the data; specifically LJ checked en-
tries on trial description and VV checked entries on trial findings.
If there had been any discrepancies, the other review authors would
have been consulted and discrepancy resolved by consensus.
Assessment of risk of bias in included studies
Two authors independently assessed risk of bias for each study us-
ing the criteria outlined in the Cochrane Handbook for Systematic
Reviews of Interventions, resolving any disagreements by discussion
(Higgins 2011). We completed a ’Risk of bias’ table for each in-
cluded study. We assessed the following for each study.
• Random sequence generation (checking for possible
selection bias). We assessed the method used to generate the
allocation sequence as: low risk of bias (any truly random
process: random number table; computer random number
generator); and unclear risk of bias (method used to generate
sequence not clearly stated). We excluded studies using a non-
random process, which were therefore at high risk of bias (odd or
even date of birth; hospital or clinic record number).
• Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
before assignment determines whether the intervention
allocation could have been foreseen in advance of, or during,
recruitment, or changed after assignment. We assessed the
methods as: low risk of bias (telephone or central randomisation;
consecutively numbered, sealed, opaque envelopes); and unclear
risk of bias if the method was not clearly stated. We excluded
studies that did not conceal allocation, which were therefore at
high risk of bias (open list).
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• Blinding of participants and personnel (performance bias).
We assessed the methods used to blind study participants and
outcome assessors from knowledge of which intervention a
participant received. We assessed the methods as: low risk of bias
if the study stated that it was blinded and described the method
used to achieve blinding: identical tablets, matched in
appearance and smell; and unclear risk of bias if the study stated
that it was blinded but did not provide an adequate description
of how blinding was achieved. We judged a study as high risk if
there was no blinding or incomplete blinding, and the outcome
was likely to have been influenced by lack of blinding. We also
judged a study as high risk if blinding was attempted but it was
likely that the blinding could have been broken and the outcome
was likely to be influenced by lack of blinding.
• Incomplete outcome data (attrition bias). We assessed
whether there was attrition bias due to the amount, nature or
handling of incomplete outcome data. We judged the study as
having low risk of attrition bias if there were no missing outcome
data or the reasons for missing data were unlikely to be related to
true outcome, or missing data and reasons for it were similar
across trial arms, or the missing data had been imputed using
appropriate methods. We judged the study as high risk if the
reason for missing outcome data was likely to be related to the
outcome, with either imbalance across trial arms in numbers of
reasons for missing data and if an inappropriate application of
simple imputation was potentially used. We judged the study as
unclear risk if there was insufficient reporting of attrition to
permit judgement of low or high risk.
• Sample size (checking for possible biases confounded by
small size). Small studies have been shown to overestimate
treatment effects, probably because the conduct of small studies
is more likely to be less rigorous, allowing critical criteria to be
compromised (Zhang 2013). We considered studies to be at low
risk of bias if they had 200 participants or more, at unclear risk if
they had 50 to 200 participants, and at high risk if they had
fewer than 50 participants.
• Selective outcome reporting (checking if there was a
selection of a subset of the original variables recorded on the
basis of the results). We assessed selective outcome reporting, if a
protocol was available, by comparing outcomes in the protocol
and published report. If they were the same we assessed it as low
risk in this domain, if they differed we considered it as high risk.
If a protocol was not available, then we compared the outcomes
listed in the methods section of an article with the outcomes for
which results were reported. If they differed we considered the
study as high risk. If a protocol was not available and even
though the outcomes listed in the methods section and the
results section were the same, we considered the study as having
an unclear risk of bias in this domain.
We incorporated the results of the ’Risk of bias’ assessment into the
review through systematic narrative description and commentary
about each item.
Measures of treatment effect
Treatment effects were measured using dichotomous data or ordi-
nal rating scales.
Dichotomous data
Where dichotomous data were reported (if data were available) we
planned to extract or generate odds ratios (ORs) and their 95%
confidence intervals (CIs) where appropriate.
Continuous data
We assessed effect measures for ordinal data as continuous data.
Where continuous data were reported, we planned to extract or
generate the mean difference (MD) from the means and standard
deviations.
Unit of analysis issues
For any identified cluster-randomised controlled trials we planned
to check for errors in the unit of analysis and, if errors were found
and sufficient data were available, to recalculate the results using
the appropriate unit of analysis (Higgins 2011). For data arising
from RCTs with a cross-over design, if available, we planned to
use in any combined analysis only data from the first comparative
phase prior to cross-over. This decision was based on the possibil-
ity of a ’carry-over’ of treatment effect from the experimental or
comparative treatment.
Dealing with missing data
Missing studies can result from an inadequate search for data or
from publication bias in that papers with negative findings are
less likely to be published. How we dealt with this is detailed in
Search methods for identification of studies and in Assessment
of reporting biases.
We anticipated finding a significant amount of loss to follow-up in
this review.Thiswas due either to the patient’s declininghealth and
the caregiver’s need for more time with their loved one, or because
of the death of the patient. We report attrition rates, per trial, in
the ’Risk of bias’ tables (see Characteristics of included studies).
This included, if available, per trial arm reasons for attrition, and
whether the trial analysis entailed any re-inclusions. We did not
undertake any imputation for missing participant data.
A common item missing in outcome data is the standard devia-
tion for continuous outcomes. Where data were not reported, but
might be available, we attempted to contact the study authors. We
attempted contact with them up to two times. If contact with the
author was not possible, we planned to calculate or impute this us-
ing relevant data, only if aminority of the trials (to be combined in
a meta-analysis) had amissing standard deviation (Higgins 2008).
If we had undertaken such imputation we planned to perform
sensitivity analyses to assess its impact on combined analysis.
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We did not exclude trials on the basis of missing data. In the
Discussion section we address the potential impact of missing data
on the findings of the review.
Assessment of heterogeneity
If meta-analysis had been possible, we would have assessed statisti-
cal heterogeneity between trials using the Chi2 test and I2 statistic
(a Chi2 P value of less than 0.05 or an I2 value equal to or more
than 50% is considered to indicate substantial heterogeneity). If
substantial heterogeneity was identified, we planned to undertake
subgroup analyses to investigate its possible sources.
Assessment of reporting biases
Ifmeta-analysis had been possible wewould have sought to explore
publication bias visually using funnel plots. In our interpretation
of the plotswe planned touse theCochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Data synthesis
For any combined analysis that had been possible, as the patient
populations were quite variable in age and treatments (as were
the interventions), wewould have employed random-effects meta-
analyses.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis explores whether the overall effect varies with
different trial populations and with the nature and content of the
interventions. In this update we planned the following subgroup
analysis:
• trials of participants with severe sexual dysfunction;
• trials of participants with advanced cancer.
Sensitivity analysis
We planned to perform sensitivity analyses in order to explore (by
excluding trials) the influence of the following factors:
• unpublished trials;
• trials with high risk of bias.
R E S U L T S
Description of studies
Results of the search
In this 2015 update we searched for both interventions for men
and women; two review authors independently screened 85%
of 4218 citations identified. Thirty studies evaluating interven-
tions for women appeared to be relevant at citation assessment. At
full-text assessment, 11 studies were eligible (Aktas 2015; Barton
2007; Baucom 2009; Classen 2013; Lee 2011; Marcus 2010;
Rowland 2009; Schover 2011; Schover 2013; Svensk 2009; Yang
2012). We found two further articles at full-text assessment that
related to studies in progress (DuHamel 2013; Schofield 2013)
(see Characteristics of ongoing studies) and we excluded seven fur-
ther articles because they did not fulfil the inclusion criteria, as
they did not report sexual outcomes or were not a RCT. Details
of these studies and those excluded in the original review (and
involving populations of women) are in the table Characteristics
of excluded studies. We found seven studies that are awaiting clas-
sification (see Characteristics of studies awaiting classification).
The interventions for men identified in this updated search are
reviewed in another Cochrane review, which is in progress. The
search process is documented in Figure 1.
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Figure 1. Study flow diagram.
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We excluded one RCT identified in the original review in this
update as it no longer fitted our tighter inclusion criteria, as it is a
preventative intervention (Pitkin 1971).
Included studies
The 11 completed trials randomised 1509 female participants
(Aktas 2015; Barton 2007; Baucom 2009; Classen 2013; Lee
2011;Marcus 2010; Rowland 2009; Schover 2011; Schover 2013;
Svensk 2009; Yang 2012).
The trials were undertaken in populations from four countries.
Most were undertaken in US populations (Aktas 2015; Barton
2007; Baucom 2009; Marcus 2010; Rowland 2009; Schover
2011; Schover 2013). Others were undertaken in Canada (Classen
2013), South Korea (Lee 2011; Yang 2012), and Sweden (Svensk
2009).
One of the trials was of cross-over design (Barton 2007); the re-
mainder were of parallel design. Three of the studies were feasi-
bility or pilot trials (Baucom 2009; Classen 2013; Yang 2012).
Two studies compared different forms of delivery of an interven-
tion (Schover 2011; Schover 2013), and two used wait-list con-
trols (Classen 2013; Schover 2011). Four trials involved samples of
fewer than 50 participants (Baucom 2009; Classen 2013; Svensk
2009; Yang 2012). Four had samples of over 100 participants
(Barton 2007;Marcus 2010;Rowland 2009; Schover 2011).None
of the trials reported drug, staff or project pharmaceutical funding
or affiliation.
All trials involved participants that had breast or gynaecological
cancer.Where reported, themean age of participants ranged across
trials from 44 to 57 years. The treatments the participants under-
went for cancer were surgery, radiation, endocrine therapy and/or
chemotherapy.
As per the inclusion criteria participants in the majority of tri-
als had documented poor sexual functioning following a can-
cer treatment (Barton 2007; Baucom 2009; Classen 2013; Lee
2011;Marcus 2010; Rowland 2009; Schover 2011; Schover 2013;
Svensk 2009;Yang 2012).We included another trial as the authors
were explicit in assuming that for a high proportion of the par-
ticipants the cancer treatment would result in sexual dysfunction
(Aktas 2015). Across the studies how sexual dysfunction was mea-
sured varied. This included self report and scales specifically de-
veloped for the project. Validated tools used included the Changes
of Sexual Functioning Questionnaire (Clayton 1997), Derogatis
Inventory of Sexual Functioning (Derogatis 1979), the Female
Sexual Distress Revised Scale (Derogatis 2008), Female Sexual
Function Index (Rosen 2000), and the sexual function subscale of
the Australian Pelvic Floor Questionnaire (Baessler 2009). Only
one trial specifically set out to only include those with severe sex-
ual dysfunction (Classen 2013), although in two other trials the
scores obtained on the scales used for sexual dysfunction suggested
overall a significant problem (Lee 2011; Schover 2011). One trial
evaluated sexual outcomes in both the women and their partners
(Baucom 2009).
All involved participants were in a couple relationship, although
only two of the trials documented that participants were sexually
active prior to the cancer treatment (Aktas 2015; Classen 2013).
In three trials the intervention was started during active treatment
for cancer of surgery, radiography or chemotherapy (Aktas 2015;
Baucom 2009; Svensk 2009); for one of these studies the treat-
ment, radiology, was ongoing (Svensk 2009). In one other trial the
interventionwas started just after the treatment for cancer (Marcus
2010). In another the mean number of months since treatment
for cancer ended was 24.3 in the intervention group and 31.3 in
the control group (Classen 2013). In the remaining six trials time
since cancer treatment was not reported (Barton 2007; Lee 2011;
Rowland 2009; Schover 2011; Schover 2013; Yang 2012).
In three trials the effect of the intervention on sexual dysfunction
was the primary focus (Aktas 2015; Barton 2007; Schover 2013).
In five of the other trials there was no declared primary outcome;
in four of these sexual dysfunction was one of several measures
of wellbeing, including quality of life, mental health and distress,
body image, spiritual wellbeing and personal growth (Baucom
2009;Marcus 2010; Schover 2011; Svensk 2009). In the fifth trial
the other measures related to the impact of an exercise interven-
tion on pelvic floor muscles (Yang 2012). In the other two in-
cluded studies sexual dysfunctionwas a secondary outcome; in one
the primary outcome was feasibility of the intervention (Classen
2013), and in the other mental health (Rowland 2009).
Further details on these trials are documented in the table
Characteristics of included studies.
Trial interventions
The interventions evaluated were pharmacological, psychothera-
peutic, psycho-educational or exercise.Most trials (8/11) evaluated
an intervention involving psychotherapeutic techniques. Within
these interventions there was heterogeneity in content.
Pharmacological interventions
Two types of pharmacological interventions were tested:
• Topical testosterone cream;
• Vaginal pH-balanced gel.
Psychotherapeutic/psycho-educational
The focus and delivery of the psychotherapeutic and psycho-edu-
cational interventions varied and included:
• Art therapy;
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• Counselling one to one, in group or by telephone. This
included professional counselling or peer support. Topics
included discussion of sexual matters, relationship functioning,
quality of life and information on treatment;
• Relationship enhancement;
• Web-based support and information.
Exercise
• Pelvic floor exercises with and without biofeedback.
Further descriptions of the included trials can be found in the
Characteristics of included studies table.
Outcomes evaluated
There was variation across the trials in how the effect of the inter-
vention on sexual function was measured, as well as for other types
of outcomes, including quality of life and psychological function-
ing. Where there was overlap, the trials differed in how they pre-
sented their results.
Excluded studies
We excluded 49 studies in the previous version of this review and
19 at this update.
The main reasons for exclusion of studies were that the report was
a discussion paper, not a RCT, the study did not include cancer
patients or that the evaluation had no sexual function outcomes.
Reasons for exclusion for all excluded studies are listed in the
Characteristics of excluded studies table.
Ongoing studies
There are seven relevant trials in progress (Davis 2015; DuHamel
2013; Gessler 2015; Hummel 2015; NCT00459134 2015;
NCT02091765 2015; Schofield 2013). The trials vary. For ex-
ample, one of the studies in progress is testing a psychothera-
peutic intervention in female survivors of anal or rectal cancer
(DuHamel 2013); another is testing a psychotherapeutic inter-
vention in women following treatments for gynaecological cancer
(Schofield 2013). Further details on these trials are documented
in the table Characteristics of ongoing studies.
Risk of bias in included studies
All trials were vulnerable to a number of biases, most commonly
selection bias. See Figure 2 and Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Most trials (n = 8) did not report the method of randomisa-
tion sequence generation (Aktas 2015; Barton 2007; Baucom
2009; Classen 2013;Marcus 2010; Rowland 2009; Schover 2011;
Schover 2013). The method concealment of allocation was de-
scribed adequately in three of the trials (Barton 2007; Baucom
2009; Svensk 2009).
Blinding
Two trials were at a low risk of performance bias (Barton 2007;
Baucom 2009).
In the other trials the risk was either high, as the authors stated
that the trial was single-blinded, or the risk was unclear as they
provided no details.
Incomplete outcome data
The risk of attrition bias was low in most trials (n = 6) (Barton
2007; Baucom 2009; Classen 2013; Marcus 2010; Svensk 2009;
Yang 2012).
Selective reporting
The risk of selective reporting was unclear in most studies (n =
8) as they did not reference a protocol or clearly state primary
outcomes.
Other potential sources of bias
Seven trials were at a high risk of bias as they involved fewer than 50
participants in each trial arm (Aktas 2015; Baucom 2009; Classen
2013; Lee 2011; Schover 2013; Svensk 2009; Yang 2012).
Effects of interventions
The effects of the interventions are reported as fully as possible.
Some trials did not report for all outcomes assessed the actual
scores for or number of participants experiencing an outcome.
Pharmaceutical interventions
Two trials evaluated a pharmaceutical intervention.
Testosterone cream versus placebo
One cross-over trial of 150 women with cancer evaluated the ef-
fect of testosterone 2% in Vanicream versus plain Vanicream in
the control group (Barton 2007). As per the inclusion criteria, at
baseline all participants had a decrease in sexual desire. This was
defined as a score of less than 8 on a 0- to 10-point scale with
10 being highest interest (actual scores not provided). Participants
were instructed to apply a spoonful of the cream (intervention
treatment or control) onto a large area of their abdomen or thighs.
The trial reported cross-over periods separately and so according
to our protocol we only report the pre-cross-over results.
Sexual function
Outcomes for sexual desire/interest and frequency of desire were
captured using the Changes in Sexual Functioning Questionnaire
(CSFQ) (Clayton 1997). The overall score for the scale runs from
0 to 100, with higher scores representing poorer outcome.
Using the CSFQ for the summed score of desire/interest and fre-
quency of desire it was found that there was no significant dif-
ference in effect between the trial arms. The first cross-over mean
score in the intervention group was 48.53 and in the control group
it was 44.41. The mean difference (MD) in change from baseline
was 1.08 (95% confidence interval (CI) -2.78 to 4.94). Neither
was there a significant difference in the CSFQ subscale on feelings
of sexual pleasure (MD 4.67, 95% CI -0.10 to 9.44) (see Table 1
for the actual scores).
Quality of life
Quality of life was not measured.
Adverse effects
The trial reported no significant difference between trial arms in
adverse effects of acne, voice deepening, abnormal hair loss or
growth, peripheral oedema or headache. The actual numbers of
participants suffering these events were not reported.
Secondary and other outcomes
The Profile of Mood States (POMS) was used to measure psycho-
logical function. They also reported the findings of a subscale on
vitality. There was no significant difference between trial arms for
both outcomes (MD -3.37, 95% CI -8.15 to 1.01; MD -2.20,
95% CI -6.84 to 2.44) (see Table 1 for the actual scores). Impact
on physical symptoms of cancer were not reported.
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pH-balanced vaginal gel versus placebo
In one trial, 98 women with breast cancer were randomised to
either apply three times a week a pH-balanced vaginal gel or a
placebo gel (Lee 2011). The women had experienced menopause
after chemotherapy or endocrine therapy. In both trial arms, par-
ticipants at baseline reported a high degree of dyspareunia. On a
scale of 0 to 10 with 10 being the highest score for dyspareunia,
the baseline mean in the intervention group was 8.23 (standard
deviation (SD) 0.99) and in the control group 8.20 (SD 0.95).
Likewise the score (using the same scoring system) for vaginal dry-
ness with pain was high: in the intervention group it was 8.20 (SD
0.83) and in the control group 7.92 (SD 0.89).
Sexual function
Effectiveness of the gel was measured by whether it reduced dys-
pareunia and vaginal dryness. This was measured using a visual
analogue scale of 0 to 10 with higher scores reflecting poorer func-
tion/more severe symptoms.
At 12 weeks of treatment there was a significant difference favour-
ing those in the intervention group in reduced dyspareunia and
other measures of vaginal health, including reduced vaginal dry-
ness (mean dyspareunia 5.48 (SD 1.06) in the intervention group,
mean dyspareunia 6.11 (SD 1.42) in the control group; MD -
0.63, 95% CI -1.13 to -0.13); mean vaginal dryness 4.23 (SD
1.40) in the intervention group and 6.51 (SD 1.51) in the control
group; MD -2.28, 95% CI -2.85 to -1.71).
Quality of life
Quality of life was not measured.
Adverse effects
The most common adverse effect was the sensation of vaginal
burning or irritation; there was no significant difference between
the trial arms in the proportions of women experiencing this (18/
49 in the intervention group versus 13/49 in the control group;
odds ratio (OR) 1.61, 95% CI 0.68 to 3.80). There were no
reported severe adverse effects.
Secondary and other outcomes
Impact on symptomsof cancer andpsychological functioningwere
not reported.
Psychotherapeutic and psycho-educational
Eight trials assessed the effectiveness of a psychotherapeutic inter-
vention or psycho-educational intervention (Aktas 2015; Baucom
2009; Classen 2013;Marcus 2010; Rowland 2009; Schover 2011;
Schover 2013; Svensk 2009). The content of four interventions
was specific to sexual matters (Aktas 2015; Baucom 2009; Classen
2013; Schover 2013). Three were broader in topic, covering in
addition to sexual matters other quality of life issues such as phys-
ical, psychological, social and spiritual wellbeing (Marcus 2010;
Rowland 2009; Schover 2011). The intervention in the other trial
was art therapy and it did not explore sexualmatters (Svensk 2009).
Instead it provided participants with a medium for expression and
reflection. It was included as sexual functioning was a specific out-
come. The interventions not only varied in content, but in how
they were delivered and in their comparison. In brief:
• Specialist nurse counselling on sexual matters (Aktas 2015).
The comparison group received usual post-cancer treatment care;
• Face-to-face counselling on relationship enhancement
compared with an active control of provision of a list of support
services (Baucom 2009);
• Online support group to address the psychosexual impact
of cancer compared with a wait-list control (Classen 2013);
• Telephone counselling on living with physical change,
sexuality, relationships and economic change compared with an
active control of a list of support services (Marcus 2010);
• Sexual relationship enhancement intervention compared to
an active control of an educational leaflet (Rowland 2009);
• Peer counselling aiming to improve knowledge and reduce
symptoms relating to sexual dysfunction compared to
participant-initiated call to receive brief telephone counselling on
sexual dysfunction (Schover 2011);
• Online intervention on sexual and fertility consequences of
cancer and treatment (Schover 2013). Participants’ use of the
website was guided by a counsellor in one trial arm and not in
the other arm;
• Art therapy intervention compared with a control group
who had usual care (Svensk 2009).
Detailed information regarding treatment arms and outcomes is
provided in the Characteristics of included studies.
This diversity and complexity of interventions precluded any tax-
onomy of simple labels that would accurately summarise efficacy
per intervention type. It also precluded classification into gen-
eral themes and groups. Moreover the trials varied in how they
measured impact on sexual functioning, with five not reporting
their findings in a way that was appropriate for combined analy-
sis (Baucom 2009; Marcus 2010; Rowland 2009; Schover 2011;
Schover 2013). Therefore for these reasons their results are pre-
sented individually.
Results
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Three studies found that a psychotherapeutic or psycho-educa-
tional intervention had a beneficial effect on somemeasures of sex-
ual function (Aktas 2015; Baucom 2009;Marcus 2010). In others
the benefit of the intervention was either unclear (Rowland 2009;
Schover 2013), or no difference was found in sexual function in
comparison with the control intervention (Classen 2013; Schover
2011; Svensk 2009). Two trials reported a significant improve-
ment in quality of life in the intervention group compared to the
control group (Baucom 2009; Svensk 2009), but in another no
difference was found (Schover 2011). Only one study specifically
set out to measure adverse events (Baucom 2009). Four studies
evaluated psychological health, such as symptoms of depression
or anxiety (Baucom 2009; Marcus 2010; Rowland 2009; Schover
2011), and four evaluated physical functioning, impact on symp-
toms of cancer or impact of treatment on menopausal symptoms
(Baucom 2009; Schover 2011; Schover 2013; Svensk 2009).
Aktas 2014
Aktas 2015 tested whether a specialist nurse counselling service
compared to usual care would improve sexual satisfaction in 70
women following a hysterectomy for gynaecological cancer. Sexual
dysfunction was not measured at baseline, however the authors
assumed that most of the women would develop sexual problems
because of their cancer treatments. The nurses visited the women
in the intervention group three times a week until hospital dis-
charge, and subsequently at home at one and 12 weeks. The nurse
discussed sexual problems with the women including body image,
self confidence, the fear of being rejected, loss of desire, sexual
intercourse, vaginal sensitivity, vaginismus, dyspareunia, inability
to reach orgasm, shortening of the vagina and incomplete penis
penetration.
Sexual function
Sexual outcomes were measured using the Golombok Rusk In-
ventory of Sexual Satisfaction (GRISS), which involves 28 items
graded on a Likert scale (Rust 1985). It provides a total score on
satisfaction with sexual function and scores for 12 subscales of
which seven were assessed in this study. The lower the scores the
greater the sexual function.
At 12 weeks, using the total score for the GRISS, there was a
statistically significant difference favouring the intervention group
(mean 7.15 in the intervention group and 9.46 in the control
group (MD -1.40, 95% CI -2.27 to -0.53).
There were mixed outcomes on the GRISS subscales. There was
significantly more improvement in the intervention group in:
• sexual non-communication (MD -1.63, 95% CI -2.52 to -
0.74);
• anorgasmia (difficulty reaching orgasm) (MD -1.73, 95%
CI -2.56 to -0.90);
• avoidance (MD -2.11, 95% CI -3.65 to -0.57);
• non-sensuality (MD -1.93, 95% CI -3.45 to -0.41).
There was no significant difference between the trial arms in:
• frequency of sexual contact (MD -0.11, 95% CI -1.01 to
0.79);
• vaginismus (MD -1.27, 95% CI -2.91 to 0.37);
• sexual dissatisfaction (MD 0.43, 95% CI -0.66 to 1.52).
• the proportion of women who had resumed sexual relations
by 12 weeks (7/35 in the intervention group and 10/35 in the
control group; OR 2.36, 95% CI 0.88 to 6.34).
Actual scores on the subscales are reported in Table 2.
Quality of life and adverse effects
Quality of life and adverse effects were not reported on.
Secondary and other outcomes
No other outcomes were reported.
Baucom 2009
Baucom 2009 conducted a pilot study of 14 couples, in which
the wife had early-stage breast cancer. Mean baseline sexual func-
tioning in both trial arms using the sexual drive and relationship
subscale of the Derogatis Inventory of Sexual Functioning (DISF-
SR) suggested a level of sexual dysfunction. Higher scores sug-
gested greater sexual function, drive and satisfaction, and better
relationship. For both trials arms the score was below mid-score
(16) on this subscale, with a mean score of 11.50 in the interven-
tion group and a mean score of 10.33 in the comparison group.
All women had received cancer treatment and in most cases it in-
volved surgery. Couples were randomised to either counselling for
relationship enhancement or an active control of provision of a
list of community support services. The intervention used a cog-
nitive behavioural approach and consisted of six sessions in which
the therapist discussed with the couple how to share feelings and
thoughts and to reach decisions jointly. The focus was on cancer-
related topics including fear, mortality, sexuality and body image.
The small number of participants meant that inferential statistics
were not used. Instead the researchers looked at between-group
effect sizes, taking into account in their analysis the change scores
for each participant. They reported that overall there was greater
improvement in couples in the intervention group in all outcomes
in relation to relationship and sexual functioning.
Sexual function
The outcomes were sexual functioning and drive using a four-item
domain of the DISF-SR of which the mean in the intervention
group 13.00 (SD 3.11) and in the control group 9.80 (SD 5.93);
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Quality of life
Relationship satisfaction was assessed using the Quality of Mar-
riage Index (QMI), with higher scores indicating greater quality.
QMI mean in the intervention group 39.71 (SD 3.45) and in the
control group 40.20 (SD 5.07).
Adverse effects
No adverse effects were reported.
Secondary and other outcomes
They reported fewer overall physical symptoms secondary to can-
cer treatment, such as nausea and dizziness, in the intervention
group compared to the control group. The study did not report
any general measures of psychological functioning. See Table 3 for
the actual scores for all outcomes reported.
Classen 2013
Classen 2013, in a feasibility study, included 27 women who were
sexually distressed following gynaecological cancer treatment. In
this trial they sought to identify women whose distress was “above
and beyond what might ordinarily occur for women with gynae-
cologic cancer”. This was defined as scoring at least 24 on the
Female Sexual Distress Revised Scale. This is higher than the rec-
ommended cutoff of 11 for sexual distress. Actual baseline scores
were not provided.
The women had received, on average two to three years earlier,
surgery, chemotherapy or radiotherapy for gynaecological cancer
and were randomised in the study to an online support group, Gy-
neGals, or a wait-list control. The aim of the 12-week online sup-
port group was to address the psychosexual impact of cancer and
its treatments. It involved a closed group discussion forum mod-
erated daily by two psychologists, who posted weekly a message
on the forum to introduce discussion topics such as coping with
emotional challenges or exploring sexuality. A dedicated website
provided psycho-educational material to support the discussion.
Sexual function
Sexual function was measured using the Female Sexual Distress
Scale (FSDS).
No significant difference was found on sexual distress using the
FSDS between those who received psychosexual support com-
pared to the wait-list control group in an intention-to-treat anal-
ysis or in an analysis of only those who actively used the forum
(MD 2.28, 95% CI -2.15 to 6.71; MD 3.56, 95% CI -2.26 to
9.38, respectively). See Table 4 for the actual mean scores.
Quality of life and adverse effects
Quality of life and adverse effects were not measured
Secondary and other outcomes
Themain outcome of this studywas feasibility and they found that
themajority ofwomen found thewebsite content to be appropriate
(15/21) and felt comfortable about discussing their sexual concerns
(14/21) in a forum. Using the Hospital Anxiety and Depression
Scale (HADS) and the Illness Intrusion Rating Scale there was no
significant difference in psychological functioning (for example,
for HADS intention-to-treat analysis: MD 0.13, 95% CI -2.44
to 2.70). See Table 4. Physiological functioning and impact on
physical symptoms of disease were not reported.
Marcus 2010
Marcus 2010, in a multi-centre study, included 304 women who
had just completed treatment for breast cancer, which in the ma-
jority of cases (74%) involved chemotherapy. Sexual function was
measured by using a 25-item scale, which was composed of ques-
tions developed specifically for the project. Scores ranged from 0
to 100 with higher scores indicating greater sexual dysfunction. At
baseline participants on average had a level of sexual dysfunction,
as suggested by mean scores between 40 and 50 (actual scores not
provided). The 152 participants randomised to the intervention
received 16- to 45-minute telephone counselling sessions on topics
regarding living with physical change, sexuality, relationships and
economic change. Those randomised to the comparison group re-
ceived a mailed booklet listing services in the community relevant
to breast cancer.
Their findings were from a before and after comparison in each
trial arm. They were not a direct comparison of effects between
the trial arms.
Sexual function was measured at follow-up as it was for baseline.
The Impact of Events Scale was used to measure cancer-specific
distress and theCenter for Epidemiologic StudiesDepression Scale
to measure depression.
Sexual function
For sexual function they reported an overall significant improve-
ment in the intervention group in mean changes scores from base-
line at 12 and 18 months follow-up (at 18 months the effect size
was 0.23, P value = 0.04), and likewise for “personal growth”, de-
scribed as deriving benefit from the cancer experience at 12 and
18 months (at 18 months the effect size was 0.22, P value = 0.03).
The comparison group showed no change from baseline. The ac-
tual scores on these scales per trial arm were not reported.
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Quality of life and adverse effects
Adverse effects were not reported and neither were outcomes for
quality of life.
Secondary and other outcomes
In both trial arms there was an improvement when comparing
mean scores for cancer-specific distress and depression. Outcomes
on symptoms of disease were not reported. The actual scores on
these scales per trial arm were not reported.
Rowland 2009
Rowland 2009 studied 155 women treated for breast cancer who
were randomised to either a psycho-educational programme or
an active control involving an educational leaflet entitled ’Facing
forward: a guide for cancer survivors’. All who were invited onto
the trial had reported that they had problems with body image,
sexuality and intimacy and/or communication with a partner. At
baseline on a scale of 1 to 6, with higher scores indicating a better
outcome, pain with sex was 4.1 in the intervention group and
4.3 in the control group. The intervention consisted of six two-
hourweekly groupmeetings, which aimed to enhance participants’
communication skills, reduce anxiety in intimate situations and
provide information on sexual anatomy, menopause and sexual
dysfunction.
Sexual function
The study’s secondary outcomes were sexual function, via Likert
scale (scores range from 1 to 6) items on satisfaction, pain and
comfort, and relationship functioning using the Revised Dyadic
Adjustment Scale (scores range from 0 to 69). For both outcomes
the higher the scores the better the function. Baseline relationship
functioning was 50.4 in the intervention group and 50.8 in the
control group.
No significant differences were found in mean change scores from
baseline to four-month follow-up between the trial arms in sexual
satisfaction in regards to variety of sex and sexual relationship out-
comes (MD 0.13, 95%CI -0.24 to 0.50; MD0.10, 95%CI -0.30
to 0.50, respectively). Neither were there significant differences
for most other outcomes relating to sex and relationships:
• pain interfering with pleasure (MD 0.30, 95% CI -0.12 to
0.72);
• improved comfort with sexuality (MD 0.20, 95% CI 0.00
to 0.40);
• comfort about being touched (MD -0.20, 95% CI -0.23 to
0.63);
• comfort in undressing (MD 0.40, 95% CI -0.21 to 1.01);
• comfort in being nude (MD 0.40, 95% CI -0.06 to 0.86);
• impact of cancer on sex (MD -0.10, 95% CI -0.37 to 0.17).
However, in the case of pain during sexual activity, impact on
relationship and communication there were significant differences
favouring those in the intervention group (MD 0.80, 95% CI
0.20 to 1.40; MD 2.40, 95% CI 1.02 to 3.78, MD 0.30, 95% CI
0.07 to 0.53, respectively). See Table 5 for the actual mean scores.
Qaulity of life and adverse effects
Adverse events were not reported and neither were outcomes for
quality of life.
Secondary and other outcomes
The study’s primary outcome was mental health using the Mental
Health Index-32. The index provides a total score with higher
scores indicating better mental health. There was no significant
difference in mean change in score from baseline to follow-up in
those in the intervention group compared to those in the control
group (MD3.10, 95%CI -0.18 to 6.38). See Table 5 for the actual
mean scores.
Outcomes on impact on symptoms of disease were not reported.
Schover 2011
Schover 2011 randomised 300 African American women who
were breast cancer survivors to either receiving a workbook and
regular peer counselling or a workbook and participant-initiated
telephone counselling. Participants at baseline had sexual dysfunc-
tion as defined on the Female Sexual Function Index (FSFI), with
amean score across the sample of 18.2 (the recommended score for
indicating sexual dysfunction is less than 26.5 (Conaglen 2010)).
The intervention workbook was designed specifically for African
American women to improve knowledge and reduce symptoms
relating to sexual dysfunction,menopause and distress about infer-
tility. In the peer counsellor group participants met the counsellor
individually three times a week for six weeks. Each session focused
on a chapter of the workbook. The telephone counselling group
were given the workbook and the counsellor’s contact details and
they were encouraged to call her.
The trial measured a range of outcomes at six and 12 months,
which included spiritual wellbeing using the Functional Assess-
ment of Cancer, relationship functioning using the Dyadic Ad-
justment Scale, emotional distress using the Brief Symptom In-
ventory (BSI), mental distress using the Global Severity Index and
sexual function using the FSFI.
Sexual function
Using mixed model analysis they found overall no significant
change across time in either group in sexual function.The exact
scores for this outcome are not provided by the authors.
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Quality of life and adverse events
Adverse effects were not reported and neither were outcomes for
quality of life.
Secondary and other outcomes
Using mixed model analysis they found overall no significant
change across time in either group in relationship functioning,
in total score for menopausal symptoms or childbearing distress.
They found depression decreased after treatment in the peer-coun-
selled group to less than 2.5 but increased in the telephone-coun-
selled group to nearly 4, but by 12 months depressive symptoms
in the two groups were very similar, around a score of 3. The exact
scores for any of these outcomes are not provided by the authors.
Outcomes on physiological functioning were not reported.
Schover 2013
Schover 2013 randomised 58 women with breast or gynaecologi-
cal cancer to either receive counselling and use of a password-pro-
tected website or “self-help”, which entailed access to the website
without counselling support. All participants had some indication
at baseline of sexual dysfunction using the FSFI as indicated by a
score of less than 15 (scores for this scale ranged from 2 to 36, with
the lower the score the poorer the sexual function). Actual scores
for the participants were not provided. The intervention website
provided information on the sexual and fertility consequences of
their cancer and treatment, on management of vaginal dryness
and pain, sexual issues and pelvic floor exercises. Those in the
counselling group were given three sessions to guide them through
the website and to discuss behavioural homework. At three and
six months post-treatment sexual outcomes were measured using
the FSFI and Menopausal Sexual Interest Questionnaire (MSIQ).
Emotional distress was measured using the BSI and quality of life
using the Quality of Life in Adult Cancer Survivors scale. The
treatment effect was explored by using linear mixedmodels regres-
sion.
Sexual function
Based on the FSFI scale they found a significant treatment effect in
improved sexual function in those who received counselling (mean
change of 7.44 frombaseline to post-treatment (no SDprovided)).
However, this was not apparent in a subgroup analysis of those
who were sexually active; the authors did not provide actual data
on this. Using the MSIQ scale there was also a significant effect
in those in the counselling group (mean change score 13.22 from
baseline to post-treatment, SD not provided), but this was only
apparent to three months.
Quality of life
Quality of life was found to improve significantly in the self help
group only. Full data on this outcome was not provided by the
authors.
Adverse effects
Adverse effects were not reported.
Secondary and other outcomes
Emotional distress using the BSI at follow-up was reduced in the
self help group by 3.73, and in the counselled group by 2.63,
but this was not significant. Full data on this outcome was not
provided by the authors.
Outcomes on physiological functioning and symptoms of disease
were not reported.
Svensk 2009
Svensk 2009, in a trial of 41 women with breast cancer, tested the
effect of five weeks of individual art therapy sessions compared
with a control group who did not receive art therapy. Participants
had a reduced level of sexual function and enjoyment at the first
assessment following breast cancer treatments. This was indicated
by the lower baseline scores for the EuropeanOrganization for Re-
search and Treatment of Cancer Quality of Life module (EORTC
QLQ-BR23) subscale on sexual functioning at baseline in both
trial arms (mean 25.44 in the intervention group and 25.00 in
the control group, compared to 38.60 in the intervention group
and 30.16 in the control group at first follow-up). The therapy,
based on phenomenological methods, aimed to provide time and
space for expression and reflection, to give support in the process
of restoring body image and to act as a supporting agency.
Sexual function
The EORTC QLQ-BR23 instrument was used to measure sexual
outcomes, and the impact of treatment and cancer on symptoms
and body image. It is comprised of 23 items. A higher score for
sexual functioning indicates a better level of functioning.
After radiation treatment there was no significant difference be-
tween trial arms in sexual function at two months (MD8.44, 95%
CI-8.01 to 24.89) and at six months (MD 5.88, 95% CI -10.15
to 21.91). In the intervention group the baseline mean was 25.44
(SD 19.54) and at six months it was 43.21 (SD 24.52). In the
control group the mean at baseline was 25.00 (SD 21.97) and at
six months it was 28.33 (SD 26.55).
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There was no significant difference in sexual enjoyment at two
months (MD 2.40, 95% CI -16.61 to 21.41) or at six months
(MD -3.17, 95% CI -23.43 to 17.09). See Table 6.
Quality of life
Quality of life was measured using the Swedish version of the
World Health Organization (WHO) instrument WHOQOL-
BREF. At two and six months there was a significant difference
favouring the intervention in quality of life (MD 12.08, 95% CI
0.39 to 23.77; MD 17.50, 95% CI 7.14 to 27.86, respectively).
Adverse effects
Adverse effects were not reported.
Secondary and other outcomes
Using the European Organization for Research and Treatment of
Cancer (EORTC) QLQ-BR23 there was no significant difference
between the trial arms at two and six months follow-up in body
image, cancer therapy side effects, ’breast symptoms’, ’arm symp-
toms’, being upset by hair loss, physiological health, psychological
heath and quality of social relationships. This is apart from being
upset about hair loss at two months, where there was a significant
difference favouring those in the intervention group. See Table 6.
Physiological functioning were not reported.
Exercise
One trial of 28 women evaluated the effect of exercise on sexual
function (Yang 2012). The women had pelvic floor dysfunction
following a radical hysterectomy and pelvic lymph node dissection
for gynaecological cancer. The trial compared four weeks of pelvic
floor muscle training with a control group receiving no training.
At the start of the intervention in both trial arms the overall mean
for sexual function using the sexual function subscale of the Pelvic
Floor Questionnaire indicated sexual dysfunction. Total scores on
the scale ranged from 0 to 20. Eight items on the scale covered suf-
ficient lubrication, vaginismus, coital incontinence, vaginal laxity,
dyspareunia and ’sexual bother’. A zero score meant that there was
no problem in any of the items. In the intervention group the
mean score was 6.02 and in the control group 4.62.
Sexual function
Sexual function was measured at four weeks via self report (yes
or no), the Australian Pelvic Floor Questionnaire (APFQ) using
a four-point scoring system (0 = no problem to 3 = severe prob-
lem) and the cervical cancer-specific EORTC QLQ CX24, which
assessed function using three items. Single-item measures on the
EORTCQLQCX24were used in this study to assess sexual worry,
activity and enjoyment. The trial had mixed outcomes for sexual
function.
The trial reported no significant difference between trial arms in
the number of participants at follow-up who were sexually func-
tioning (8/12 in the intervention group compared with 5/12 in
the control group; OR 2.80, 95% CI 0.53 to 14.74). In contrast,
the mean score using the EORTC QLQ CX24 was significantly
different between trial arms, favouring those who received the in-
tervention (MD 10.30, 95% CI 1.48 to 19.12), as was the mean
change score from baseline to follow-up for sexual function using
APFQ (MD -3.20, 95% CI -5.55 to -0.85).
Using the EORTC QLQ CX24 the authors found no significant
difference between trials arms in sexual worry or enjoyment but
they found a difference in sexual activities favouring the interven-
tion group (MD -10.00, 95% CI -22.25 to 2.25; MD 2.70, 95%
CI -9.45 to 14.85; MD 18.40, 95% CI 5.18 to 31.62, respec-
tively). Actual mean scores per trial arm were not reported.
Quality of life
Quality of life outcomes were not reported.
Adverse effects
The authors stated a physical therapist and a trained evaluator
monitored adverse effects and any participants experiencing an
aggravation of pelvic floor symptoms or difficulty in continuing
the exercises was excluded from the final assessment. They did not
provide the numbers of those excluded for these events.
Secondary and other outcomes
Psychological and physiological functioning, and symptoms of
disease were not reported.
D I S C U S S I O N
This is the first update of the 2007 Cochrane systematic review
on interventions for sexual dysfunction following treatment for
cancer in women (Miles 2007). The original publication included
interventions for men and for women. It identified only one trial
of an intervention for women. This trial was not included in this
update as it no longer fitted the tighter inclusion criteria, which
excluded trials on preventative treatments. Since the original re-
view, as demonstrated in our identification of 11 new trials and
two in progress, there has been much more research interest in
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interventions for women. Three-quarters of the trials evaluated
interventions that involved a psychotherapeutic element; the oth-
ers evaluated a pharmaceutical gel, testosterone cream and a pelvic
floor exercise. The trials involved women with gynaecological or
breast cancer. Overall, the trials were mostly not of high quality as
they under-reported design features. Three were pilot or feasibil-
ity studies involving small samples and in which the primary aim
was not to test effectiveness. We did not identify any randomised
controlled trials (RCTs) that evaluated a complementary or alter-
native medicine intervention.
Summary of main results
The variation in interventions evaluated, including between those
that involved a psychotherapeutic element, is themain reason why
there is no combined analysis in this review. Psychotherapeutic in-
terventions involved sexual counselling, art therapy, peer support
or relationship therapy; overall they showed a mixed effect on sex-
ual functioning. The evidence that testosterone cream, pH-bal-
anced vaginal gel or pelvic floor exercise improves sexual function
is weak. The evidence for each of these interventions is limited
to one study and involved in three of the four studies fewer than
50 participants per arm. Evidence on potential harms was under-
reported in all studies. This is apart from the trial on a topical
cream and the one on a pH-balanced vaginal gel, which reported
no significant increase in adverse effects in those in the interven-
tion group compared to those allocated a placebo. Surprisingly
few trials assessed quality of life, mental health or physiological
functioning, therefore it is difficult to derive any conclusions on
the effect of these interventions on these outcomes. The two tri-
als of pharmaceutical interventions measured harm and neither
reported any. Only one of the psychological intervention trials
reported that no harm occurred because of the intervention; the
other trials did not measure harm.
Overall completeness and applicability of
evidence
We searched widely for evidence using 11 citation databases and
using search terms to help identify as wide a range of interven-
tions as possible. We found some notable gaps in the evidence.We
did not identify any RCTs evaluating a complementary therapy
or alternative medicine, despite trials of these interventions, such
as Ginkgo biloba, being tested in other populations. However, a
limitation is that we did not search foreign language databases,
therefore we may have missed some studies, for example Chinese
herbal medicines and acupuncture. In any further update we rec-
ommend that these need to be considered.
We also identified no completed trials of interventions that were
evaluated in populations with cancers other than breast or gynae-
cological cancer. However, one of the trials in progress is assessing
an intervention following treatment for rectal or anal cancer. This
is an important omission as colorectal cancer is one of the most
commonly diagnosed cancers and the treatment, such as surgery
and radiation, is likely to affect sexual function (Donovan 2010).
Moreover, it is known that head and neck cancer survivors strug-
gle with disfigurement and changes in body image, and have in-
creased social isolation, all of which may lead to sexual difficulties
(Low 2009; Singer 2008). Another limitation is that all trials were
undertaken in advanced western societies, with the majority being
undertaken in US populations. Therefore our findings may not
be applicable to other populations, in particular where cultural
practices in regards to sexual matters may be different.
Quality of the evidence
We could not adequately assess risk of bias in that we found all
trials to have at least one methodological item under-reported,
including blinding or randomisation sequence generation. The
quality of the evidence is also weakened as eight of the trials had
samples of fewer than 50 participants per trial arm. Some of these
were also pilot studies, the focus of which was on feasibility rather
than effectiveness.
Potential biases in the review process
We undertook a comprehensive search of 11 databases; the last
searchwas completed in September 2015.More recently published
eligible studies will be captured at the next update. We identified
seven potentially eligible studies in progress from trial registers
and conference abstracts. In further updates of this review we
recommend considerationof searching foreign language databases.
At least two authors undertook all steps of this review. This limited
the risk of errors in determining study eligibility, data extraction,
’Risk of bias’ assessment and data synthesis.
Agreements and disagreements with other
studies or reviews
There are two recent relevant systematic reviews of psychotherapy
in general populations. Both are non-Cochrane reviews evaluating
psychotherapeutic interventions in both men and women (Berner
2012; Fruhauf 2013). The review by Berner 2012 included 20 tri-
als but only two of these included women with sexual dysfunction.
They found no benefit of the interventions for women. The review
by Fruhauf 2013 included 34 trials that compared the psychoso-
cial intervention with a comparison group. They found in com-
bined analysis of five trials an improvement in sexual function in
those who received sexual skills training. However, it is important
to note that these reviews were undertaken in non-cancer popula-
tions and therefore their findings are not necessarily transferable
to the populations considered in our review.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This update found insufficient evidence for the effectiveness of
topical pharmacological treatments, psychotherapeutic interven-
tions and pelvic floor exercises. Apart from the pharmacological
treatment we found limited evaluations of any potential harms
these interventions may incur.
Implications for research
Improved diagnosis and treatments for cancer mean that more
people will be living with and surviving cancer, and of these a
significant proportion may have sexual dysfunction. Further evi-
dence is needed on treatments for sexual dysfunction from high-
quality trials with large samples that fully report key methodolog-
ical characteristics and harms. It is difficult to suggest which inter-
ventions might be most useful for further evaluation, as the trials
we evaluated were at risk of biased results. Across the trials there
was also minimal overlap in how the intervention was evaluated.
Future trials need to consider preparatory stages in intervention
development, to increase appropriateness and need, such as in the
case of psychotherapeutic interventions, for example those recom-
mended in the Medical Research Council (MRC) guidelines on
developing and evaluating complex interventions (Craig 2008).
They also need to fully report details of the intervention. Con-
sideration is also needed of the choice of outcome measures that
are appropriate to the patient population and the nature of the
intervention, such as measures of sexual function, quality of life
and mental health.
The trials evaluated in this review varied in design; some included a
comparative armwith no additional support for sexual dysfunction
and others compared the intervention arm with an active control.
Future research should consider the appropriateness of a control
group that is given no support despite sexual dysfunction. Perhaps
at the very least trialists should consider using a comparative arm
for which the provision of usual care for sexual dysfunction is
provided.
Sexual dysfunction is difficult to treat in this population as it may
result from multiple causes, not all of which are a direct outcome
of the cancer treatment. These causes include the emotional stress
of having the diagnosis and its impact on daily living, as well as
natural aging. Thus it may be a particularly difficult disorder to
treat.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aktas 2015
Methods Randomised, controlled, single-centre trial
Participants Entered trial: 70 US women with gynaecological (42% ovarian and 42% endometrial)
cancer who underwent surgery, chemotherapy or radiotherapy for their cancer. Most
(62%) had a hysterectomy and chemotherapy. Highest disease stage was 3, at baseline
45% had reached this stage. All were sexually active before treatment. SD was not
measured early in the trial, however the authors assumed that most of the women would
developed sexual problems because of the cancer treatment. 14% in both trial arms had
a higher education. The average age was 49.3 years. They were required to abstain from
sex for the first 8 weeks following surgery
Interventions Nursing care service to discuss sexual issues
Aim: to investigate the effect of a nurse care service on the sexual satisfaction of patients
with gynaecologic cancer
Interventionist: nurse
Intervention: nursing counselling service involving additional specialist nursing care and
consultancy at hospital and at home. Nurse discussed sexual issues including loss of
the body part, body image, fear of being rejected, loss of reproductive function, loss of
desire, decrease in vaginal sensitivity, decrease in sexual intercourse, decrease in vaginal
sensitivity, vaginismus, dyspareunia, inability to reach orgasm, shortening of the vagina
and incomplete penis penetration
Comparison: usual care following hospital protocols
Time since cancer treatment: at the start of the intervention patients were undergoing
cancer treatment
Intensity of intervention: nurse visits 3 times a week whilst in hospital and twice at home
at 1 and 12 weeks
Time length of intervention: not clear
Outcomes An Interview Questionnaire, Home Visit Monitoring Questionnaire and Golombok
Rust Inventory of Sexual Satisfaction (GRISS), which contains 28 items and 7 subscales




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
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Aktas 2015 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk 70 entered. 2 and 3 patients died in the in-
tervention and control groups respectively
during the whole course of the project im-
plementation
Selective reporting (reporting bias) Unclear risk Protocol not published and does not state
primary outcomes
Sample size High risk Fewer than 50 participants per trial arm
Barton 2007
Methods Randomised, cross-over, controlled, single-centre trial (phase III)
Participants Entered trial: 150 postmenopausal US female survivors of breast cancer. To be eligible
all participants needed to report a decrease in sexual desire. This was defined as a score
< 8 on a 0 to 10 scale with 10 being the highest interest. To derive this they used the
combined desire/interest (3 questions) and desire/frequency (2 questions) subscales of
the Changes of Sexual Functioning Questionnaire (CSFQ). Eligible patients had to have
a sexual partner. 131 were analysed. Mean age was 52.3 years. 80% of participants had
been treated with chemotherapy
Interventions Pharmacological
Topical cream intervention
Aim: whether transdermal testosterone would increase sexual desire in female cancer
survivors
Interventionist: no details
Intervention: daily 10.4 mg testosterone cream (Vanicream 2% testosterone) in 1/8
teaspoon
Comparison: placebo Vanicream
1 dose maximum per day
Intervention duration: 4 weeks
Time since cancer treatment: No details
Time length of intervention: 4 weeks of each of the trial arm treatments
Outcomes 1.The primary outcomewas sexual desire, whichwasmeasuredusing combined subscales
of desire/interest and desire/frequency of the CSFQ
Other scales were:
2. Derogatis Interview for Sexual Functioning/Self-Report Scale
3. Profile of Mood States
4. SF-36
Analysis at 4 and 8 weeks
Notes -
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Barton 2007 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central office, computer-generated
Allocation concealment (selection bias) Low risk Done by the central office
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients and all personnel were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 18/150 patients lost to follow-up; reasons
provided
Selective reporting (reporting bias) Low risk Clearly provides results for all primary out-
comes
Sample size Unclear risk Sample of 150; 50 to 199 per treatment
arm
Baucom 2009
Methods Randomised, parallel, controlled pilot trial
Participants Early-stage female breast cancer. Sample 14 US couples. An aim of the intervention
was to improve sexual function. Baseline sexual functioning using the sexual drive and
relationship subscale of Derogatis Inventory of Sexual Functioning was below mid-score
(16), suggesting a level of SD. Cancer treatment involved surgery (n = 11), chemotherapy
(n = 3) and radiation (n = 1). Median age was 50 years, age range 30 to 80 years
Interventions Psychotherapeutic
Directed to patient and partner. The intervention is based on a cognitive behavioural
approach that has demonstrated considerable efficacy in alleviating and preventing rela-
tionship distress
Aim: to pilot a couple-based intervention programme for breast cancer that teaches
couples how to minimise negative effects and maximise positive functioning during this
difficult time
Interventionist: clinical psychology therapists trained in couple therapy and in the effects
of cancer on relationship functioning
Intervention content: couple-based relationship enhancement
6 sessions of 75 minutes each. The sessions included (1) approaching breast cancer as
a couple, (2) medical education regarding breast cancer, (3) communication skills for
decision-making and sharing thoughts regarding cancer issues, (4) promoting healthy
sexual adaptation and body image, (5) maintaining positives in life and (5) findings
benefits and meaning in life. The content of each session could vary but the format was
similar; they began with an update of the women’s treatment for breast cancer and then
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Baucom 2009 (Continued)
reviewed homework assignments. The material provided per session was individualised
to the couple. The session closed with the therapist providing a summary of the session
and assigning the next homework session
Comparison: usual care. Couples received a list of community resources for additional
support. They did not receive cancer education or any form of psychological intervention
Duration of intervention: 6 weeks held bi-weekly
Time since cancer treatment: cancer treatment ongoing
Outcomes No primary outcome declared
1. Quality of Marriage Index (QMI)
2. Derogatis Inventory of Sexual Functioning (DISF-SR)
3. Brief Symptom Inventory (BSI-18)
4. Post-traumatic Growth Inventory (PGI)
5. Functional Assessment of Cancer Therapy (FACT-B)
6. Self Image Scale (SIS)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based random number genera-
tor
Allocation concealment (selection bias) Low risk Couples and the assessor were blind to sub-
sequent treatment assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk One couple in the intervention group
dropped out because they felt the interven-
tion did not meet their needs as the woman
required additional treatments for cancer
and one couple were lost in the control
group as the woman died
Selective reporting (reporting bias) Low risk Results for all outcomes provided
Sample size High risk Fewer than 50 participants per trial arm
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Classen 2013
Methods Randomised, controlled, parallel, single-centre feasibility trial
Participants 27 Canadian, sexually-distressed (asmeasured by scoring at least 24 on the Female Sexual
Distress Revised Scale, which is higher than the recommended cutoff of 11 so as they
identified women whose distress was “above and beyond what might ordinarily occur
for women with gynaecologic cancer”) female gynaecologic cancer patients subsequent
to cancer treatment entered the trial. The women had received surgical, medical and/
or radiation treatment for gynaecological cancer. They were currently disease-free for a
minimum of 3 months. Mean age in the intervention group was 39.9 years and in the
wait-list control 44.6 years. Age range was 28 to 59 years. Over 70% were Caucasian
Interventions Psychotherapeutic intervention
Aim: feasibility study examining the participation rates and preliminary outcomes for
an online support group designed specifically for women who are sexually distressed
subsequent to gynaecologic cancer treatment
Interventionist: psychologists co-ordinated the discussion forum
Intervention 1: ’GyneGals’, hosted on 2 websites with weekly discussion topics. One
website hosted the discussion forum, which allowed women access to an online group.
The support group was a closed group only accessible to members and the research team.
The other website housed the psycho-educational material, which was only accessible
by members and the research team. The 2 websites were linked. In week 10 of the
intervention, a 90-minute text-based chat session was offered in which the participants
could interact in real time with a gynaecologic oncologist and radiation oncologist as
well as the moderators
Comparison group: wait-list control, whenever the user wanted to (at least once a week)
Duration of intervention: 12 weeks
Time since cancer treatment: required to be disease-free for a minimum of 3 months
and no more than 5 years post-diagnosis
Outcomes The primary outcome was feasibility of the trial and intervention
The secondary outcomes were:
1. Female Sexual Distress Scale - revised, 13-item
2. HADS
3. Illness Intrusiveness Ratings Scale
4. GyneGals exit questionnaire to assess participant’s satisfaction with intervention
Follow-up at 4 and 8 months
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
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Classen 2013 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk 23/27 completed the study
Selective reporting (reporting bias) Unclear risk No details provided
Sample size High risk Fewer than 50 participants per trial arm
Lee 2011
Methods Randomised, controlled, parallel, single-centre trial
Participants 98 women entered the trial with a history of primary breast cancer managed by chemo-
therapy or hormonal therapy, experienced menopause for a period of at least 12 months
before the study, and at baseline in both trial arms on average there was a high degree
of vulvovaginal dryness with pain (with a score of 10 indicating the highest score; in
the intervention group the score was over 8.20 and in the placebo group 7.92) and
dyspareunia (with a score of 10 indicating the highest score; in both the intervention
and placebo groups it was over 8). Excluded were natural menopause, medical disease
or other complications, other malignancies, a hysterectomy or oophorectomy, use of
medication for uro-gynaecologic problems, unexplained vaginal bleeding and previous
use of systemic or local sex hormones
Mean age in the intervention group was 45 years and in the control group 44. At baseline
in both trial arms participants (or most) reported painful intercourse. Over half of the
participants were treated with chemotherapy plus hormonal therapy; the others were
treated either by chemotherapy only or hormonal therapy only
Interventions Intervention: pH-balanced gel; the gel contained lactic acid to maintain the vaginal pH
at about 4
Comparison: placebo gel (pH 7.2)
Both gels were applied via a vaginal applicator 3 times per week at bedtime
Time length of intervention: 12 weeks
Time since cancer treatment: not reported




Bias Authors’ judgement Support for judgement
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Lee 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Random assignment was made from a con-
fidential list of permuted blocks of 4 by a
third party before the study
Allocation concealment (selection bias) Low risk Random assignment was made from a con-
fidential list of permuted blocks of 4 by a
third party before the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The same-sized vaginal gel tubes with or
without lactic acid (pH 4.0 and pH 7.2,
respectively) were packaged identically by
themanufacturer and labelledwith sequen-
tial numbers according to the randomisa-
tion code
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5/49 lost to follow-up in the intervention
arm and 7/42 in the placebo arm
Selective reporting (reporting bias) Low risk Results for primary outcomes provided
Sample size High risk Fewer than 50 participants per trial arm
Marcus 2010
Methods Multi-centred, randomised, parallel, controlled trial
Participants 304 US female breast cancer patients post-treatment, which included chemotherapy,
radiation therapy, surgery and tamoxifen, entered the trial. The most common cancer
treatment was chemotherapy (226/306). Most participants were aged between 41 and
60 years. At baseline there was a level of SD as documented in a figure (degree of SD
not stated). It was assessed using a scale of 25 items of which some of the items were
developed specifically for this project
Interventions Psycho-therapeutic
Aim: to determinewhether a telephone counselling programme can improve psychosocial
outcomes among breast cancer patients post-treatment
Interventionist: psychosocial oncology counsellor
Intervention content: telephone counselling programme augmented with additional
printmaterials. Patients were given the choice to prioritise counselling on 1 of 6 themes of
the materials: these were living with uncertainty, living with physical change, living with
self change, sexuality after breast cancer, living in relationships and living with economic
change. The aim was to enhance adaptation by normalising feelings of uncertainly and
preparing survivors for unanticipated disruption across quality of life domains (physical,
emotional, social, sexual and economic). The intervention also included printedmaterial
(stress management guide), relaxation tapes, written activities (including self monitor-
ing) and feedback on progress at session 10
Comparison group: received a resource directory for breast cancer
Duration of intervention: 16 sessions of 45 minutes each over 1 year, first 9 provided at
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Marcus 2010 (Continued)
2 weekly time points
Time since cancer treatment: states “just” completed treatment for breast cancer
Outcomes Primary outcome: none declared
1. Cancer-specific distress: Impact of Event Scale (IES)
2. Depression: Center for Epidemiologic Studies Depression Scale (CES-D)
3. Sexual Dysfunction using the Sexual Dysfunction Scale (not referenced)
4. Personal growth from cancer experience: questions derived for survey
Assessment at 3, 6, 12 and 18 months
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details on randomisation
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk The response rates at each follow-up did
not differ by trial arm. 243/304 completed;
reasons not provided
Selective reporting (reporting bias) Unclear risk No details provided
Sample size Unclear risk 50 to 199 per treatment arm
Rowland 2009
Methods Randomised, parallel, controlled trial involving 3 arms; 1) Intervention, 2) Intervention
participants randomised to intervention but declined intervention but follow-up, 3)
Control group
Participants 411 US women with breast cancer who had completed all cancer therapy except Tamox-
ifen entered the trial. 294 completed the trial. Mean age 57 years in the intervention
group and 56 in the control group (range 35 to 86). Participants had either lumpectomy,
mastectomy only or mastectomy and reconstruction. Around half had also received che-
motherapy. Mean years since diagnosis: 3 years in the control group, 2.8 in the interven-
tion group. Majority (over 80%) Anglo-American. Majority (over 70%) married. Mi-
nority (third) were educated to postgraduate level. Around half of the participants were
employed. All who were invited had reported in an earlier study that they had problems
with body image, sexuality and intimacy and/or communication with a partner. Degree
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Rowland 2009 (Continued)
of sexual problems were not further detailed
Interventions Psychotherapeutic: the intervention was derived from the trialists’ conceptual model of
the development of SD in breast cancer survivors
Directed at the patient
Aim: hypothesis that women in the intervention arm would experience greater improve-
ment in their emotional wellbeing as well as body image, comfort and satisfaction with
sexual functioning and partner communication than women randomised to the control
group
Interventionist: medical social workers
Intervention content: psychoeducational group programme derived from the trialists’
conceptual model of the development of sexual dysfunction. The programme aimed to
improve satisfaction with sexual functioning and intimate relationships by providing in-
formation, enhancing communication skills and reducing anxiety in intimate situations.
To ensure quality control investigators review audiotapes of a subset of sessions
Comparison group: received an educational pamphlet: ’Facing forward: a guide for cancer
survivors’
Duration of intervention: 6 weekly 2-hour meetings
Time since cancer treatment: not stated
Outcomes Primary outcome was the Mental Health Index from the Medical Outcomes Study
Secondary outcomes included Likert scale items to measure sexual outcomes
Outcomes assessed 4 months after treatment
Notes 83/284 (29%) randomised to the intervention group did not agree to take part in the
intervention. The primary reasons were inconvenience in time or location of the sessions,
the participant’s perception that she was not distressed and did not need the intervention
and being too busy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk 95/411 lost to follow-up; no reasons stated
for loss
Selective reporting (reporting bias) Unclear risk No details provided
Sample size Low risk More than 200 participants per trial arm
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Schover 2011
Methods Randomised, parallel, controlled trial
Participants 300 African American women who were breast cancer survivors entered the trial. Par-
ticipants at baseline had sexual dysfunction using the Female SFI: the mean score across
the entire sample was 18.2 (the recommended score for indicating sexual dysfunction
is less than 26.5). Treatments for cancer varied; most commonly it was surgery and/or
chemotherapy or radiotherapy. Mean age 54 years. Time since cancer diagnosis 6.5 years
Interventions Psychotherapeutic
Directed at the patient
Aim: to assess the effectiveness of the peer counselling programme compared with brief
telephone counselling and to examine the influence of socio-medical factors on repro-
ductive problems and the outcome of the intervention
Interventionist: trained counsellors who were African American breast cancer survivors
Intervention 1: Sisters Peer Counseling involving a 77 page workbook plus 3 sessions
with a trained peer counsellor. Each 60- to 90-minute session focused on a chapter of
the workbook. Each chapter began with a list of topics (such as how to overcome vaginal
dryness) and the survivor rated the importance of each topic before the counselling
session; this helped to tailor the focus of the discussion
Intervention 2: telephone counselling, which included being sent the workbook and
being invited to call the counsellor using a prepaid telephone card for up to 30 minutes
to discuss the workbook
Duration of treatment: 3 sessions over 6 weeks
Time since cancer treatment: not stated
Outcomes Emotional distress, sexual function, relationship satisfaction, spirituality, menopause
symptoms and knowledge. Outcomes assessed up to 1 year after start of the intervention
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Minimisation techniques - a form of adaptive
randomisation. They do not provide details on
sequence generation
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
High risk 189/300
Selective reporting (reporting bias) Unclear risk No details provided
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Sample size Unclear risk 50 to 199 per treatment arm
Schover 2013
Methods Randomised, parallel, controlled trial
Participants 58US survivors of localised breast or gynaecologic cancers entered the trial. Themajority
(71%) had received chemotherapy, 7% pelvic radiation and 19% were taking tamoxifen.
Mean age 58 years. Over 59% had at least 4 years college education, the majority were
white (79%) and married (81%). 81% had breast cancer, the others gynaecologic. 54%
were at cancer stage I. Mean years since diagnosis 3.5. 48% had a comorbid condition
including diabetes, depression and hypertension. All had some indication at baseline
of sexual dysfunction using the Female Sexual Function Index (FSFI) as indicated by a
score of less than 26.5. Scores for this scale range from 2 to 36, with the lower the score
the poorer is sexual function
Interventions Web-based intervention called Tendrils: sexual renewal for women after cancer
Intervention directed at the patient
Aim: the efficacy of a trial of an Internet-based intervention for cancer-related female
sexual dysfunction with the support of 3 counselling sessions compared to when the
website is used as a self help site
Intervention: website with sections describing the sexual and fertility consequences of
their cancer and treatment, an interactive vulva self portrait with pain and pleasure
mapping, sex after menopause; management of vaginal dryness and pain; causes and
treatment options for loss of desire or orgasm problems; resuming sex. It also involved
videos of women cancer survivors and vignettes played by actors illustrating common
problems and coping strategies. A therapist manual provided guidance and content
checklists during 3 counselling sessions. These were provided by 2 masters level mental
health professionals. The counsellors guided women through the website and discussed
behavioural homework
Comparison: self help, which involved access to the website but no provision of a coun-
sellor
Duration of intervention: 12 weeks
Time since cancer treatment: unclear
Outcomes The primary outcome was the FSFI. Other outcomes were theMenopausal Sexual Inter-
net Questionnaire, the Brief Symptom Inventory, Global Severity Index and the Quality
of Life in Adult Cancer Survivors
Outcomes were assessed at end of treatment and at 3- and 6-month follow-up
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation stated, no details provided
39Interventions for sexual dysfunction following treatments for cancer in women (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Schover 2013 (Continued)
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details provided
Selective reporting (reporting bias) Unclear risk No details provided
Sample size High risk Fewer than 50 participants per trial arm
Svensk 2009
Methods Randomised, controlled, parallel trial
Participants 42 Swedish women with breast cancer who were undergoing radiotherapy entered the
trial. Median age in the intervention group was 59.5 years and in the control group
55 years. Participants had a reduced level of sexual function and enjoyment at the first
assessment following breast cancer treatments. This was indicated by the lower baseline
scores for the EORTC QLQ-BR23 subscale on sexual functioning at baseline in both
trial arms
Interventions Intervention: art therapy involving 5 individual sessions for 1 hour a week. The aim was
to offer time and space for expression and reflection, to give support in the process of
restoring body image and to reduce stress. Sessions were based on a phenomenological
method of art therapy
Comparison: no details
Intervention length: 5 weeks
Time since cancer treatment: ongoing
Outcomes Sexual functioning measured using the EORTC Quality of Life Questionnaire, version
1.0. It includes 23 items to assess as well as sexual functioning and enjoyment, disease
symptoms, side effects, body image and future perspectives
Quality of life using (1) the Swedish version of the WHO instrument WHOQOL-
BREF. This involves 26 items in 4 domains: physical, psychological, social relationships
and environment, and the (2) the European Organization for Research and Treatment
of Cancer Instrument




Bias Authors’ judgement Support for judgement
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Svensk 2009 (Continued)
Random sequence generation (selection
bias)
Low risk “computer generated”. Stratification was done
according to whether the patient had received
adjuvant chemotherapy before radiotherapy
treatment or not
Allocation concealment (selection bias) Low risk The randomisation was computer-generated at
the Regional Centre of Oncology at Umea
University
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants could not be blinded because of the
nature of the intervention; does not state that
the analyst or other personnel were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 42/42 completed the study
Selective reporting (reporting bias) Unclear risk No protocol is available and study report does
not state a primary outcome
Sample size High risk Fewer than 50 participants per trial arm
Yang 2012
Methods Randomised, parallel, controlled pilot trial
Participants 34 South Korean women with gynaecological cancer who had radical hysterectomy
entered and 24 completed trial. Study included because at the start of the intervention in
both trial arms the overall mean on sexual function using the sexual function score of the
Pelvic Floor Questionnaire indicated sexual dysfunction. Total scores in scale range from
0 to 20. 8 items on the scale cover sufficient lubrication, vaginismus, coital incontinence,
vaginal laxity, dyspareunia and sexual bother. A zero score means no problem in any of
the items. In the intervention group the mean score was 6.02 and in the intervention
group 4.62. Mean age 52 years
Interventions Exercise intervention
Intervention directed at patient
Aim: to investigate the effectiveness of this pelvic floor rehabilitation programme on
pelvic floor function and quality of life in gynaecological cancer survivors
Interventionist: physiotherapist
Intervention content: intensive pelvic floor muscle training incorporated with core exer-
cise. The exercise is with biofeedback via a vaginal silicon pressure sensor. There was also
per session a 30-minute counselling session, which involved life-style advice, evaluation
and encouragement. In the first week patients learnt about the anatomy and function of
the pelvic floor muscles
Comparison group received usual health care
Duration of intervention: weekly for 4 weeks of 45 exercises of 30 minutes duration
Time since cancer treatment: does not specify but less than 5 years
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Yang 2012 (Continued)
Outcomes Primary outcome not stated
(1) Pelvic floor dysfunction questionnaire
(2) Pelvic floor muscle strength
(3) Motor evoked potential (MEP) of the sacral nerve
(4) Patient-reported health-related quality of life (HRQOL) measured using the Euro-
pean Organization for
Research and Treatment of Cancer (EORTC) quality of life questionnaire QLQ-C30
(a 30-item multidimensional questionnaire on global health/quality of life) and the
EORTC QLQ-CX-24 (a specific cervical cancer module of patients’ experience, body
image and sexuality)
Outcomes were assessed at 4 weeks
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised, stratified block randomisa-
tion
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants not possible be-
cause of the nature of the intervention. To
avoid knowledge of an individual’s train-
ing progression and thereby potentially in-
fluencing the process of measurement the
training sessions and strength measure-
ments were administered by different peo-
ple. Outcome evaluators were blinded to
group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar in both arms and reasons provided
Selective reporting (reporting bias) Unclear risk No details provided
Sample size High risk Fewer than 50 participants per trial arm
CSFQ: Changes of Sexual Functioning Questionnaire
EORTC: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire
FSFI: Female Sexual Function Index
HADS: Hospital Anxiety and Depression Scale
SD: sexual dysfunction
WHOQOL-BREF: World Health Organization quality of life instrument
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Badger 2005 SD not mentioned
Barber 2002 Article includes sexual functioning, but cancer patients were not included
Barrett-Connor 1996 It is unlikely that these “healthy menopausal women” are cancer patients
Berman 2003 No cancer patients
Boesen 2011 No documented evidence that at the start of the intervention the participants had SD
Brotto 2012 Around half of the participants were not randomised and there was no separate analysis for those who were
randomised
Burstein 1999 This is not a RCT and alternative medicine was not an intervention for SD
Chow 2014 Does not differentiate whether the SD was before or after the cancer treatment
Christensen 1983 No baseline of SD provided
Davis 2004 Exploratory study of psychosocial needs of women with breast cancer. Not an intervention for SD following
treatments for cancer
Decruze 1999 Not a RCT
Dennerstein 1979 No cancer patients
Doorenbos 2006 No SD outcome
Floter 2002 No cancer patients
Ganz 2000 Subjects were peri or postmenopausal (they had to have been amenorrhoeic for at least 6 months). The cause
of sexual dysfunction was not studied in this sample and some women may have had problems that preceded
the cancer diagnosis or could have been attributed to treatment
Given 2004 No SD outcome
Goetsch 2014 No outcomes on sexual function
Hasenbring 1999 No SD outcome
Huang 2013 Patients with cancer were excluded
Izuo 1967 No sexual function outcomes
Jefferies 2006 No established baseline report of SD
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(Continued)
Jones 2006 No sexual function outcomes
Jung Hoon 2006 No sexual function outcomes
Juraskova 2013 No comparative arm
Kylstra 1999 Not a treatment for SD
Lengacher 2009 No sexual function outcomes
Lepore 2015 No outcomes on sexual function
Loprinzi 2011 No sexual outcomes
Marsden 2001 Subjects are postmenopausal. The cause of sexual dysfunction was not studied in this sample and some
womenmay have had problems that preceded the cancer diagnosis or could have been attributed to treatment
Moore 1999 No cancer patients
Morales 2004 Tamoxifen: not a treatment for SD
Mulhall 2006 Discussion paper
Munarriz 2002 No cancer patients
Munstedt 1998 Not evaluating treatment for SD
Narvaez 2008 Less than 50% reported sexual problems at baseline
Nho 2013 Not a RCT
Nieman 2003 No cancer patients
Nikander 2003 No sexual outcome measures
Northouse 2002 SD not specifically mentioned
Northouse 2013 Does not measure sexual function outcomes
Park 2015 Not a randomised trial
Pietrzak 2007 Not a treatment for SD
Pitkin 1971 Intervention was a preventative treatment
Ponzone 2005 Discussion article
Rawlins 1999 Discussion article
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Reese 2014 6 relevant participants; it is not clear whether for any one the sexual concerns started after treatment or prior
to treatment for cancer
Robinson 1999 No established baseline report of SD
Schover 2006 Does not provide outcomes per trial arm
Schroder 2005 Not a RCT
Scott 2004 Participants on average had poor sexual functioning prior to cancer treatment
Seidman 2000 No cancer patients
Serewel 1990 No cancer patients.
Shabani 2014 Does not measure sexual outcomes
Sherwin 1984 Not about treatments for SD following treatment for cancer
Sherwin 1985 No cancer patients
Shifren 2000a No cancer patients
Suckling 2006 Discussion paper
Sweeney 2002 Not an intervention for SD
Theobald 2002 No SD outcomes
Thompson 2003 SD is under “ other symptoms” with other non-SD symptoms, t herefore data are not evaluable
van der Meulen 2014 No sexual function outcomes
Vos 2006 No SD outcomes
Warkentin 2006 Not a RCT
Watts 1995 No cancer patients
Wei 2005 This is a poor quality report of a RCT of psychotherapy for 1 week before and 1 week after an (unspecified)
operation for cervical cancer. The baseline level of “sexual functioning” amongst participants is not reported,
either before or after the operation.
It is unclear who the male participants were and who answered the questionnaire
The sexual outcome “sexual satisfaction” is self reported using what appears to be a single question
The figures given are not explained (so it is not clear whether they are means or medians, for example)
The randomisation procedure is not well explained
Wenzel 1999 An assessment for SD and not a treatment
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Wenzel 2015 Although SD measure d it is part of a global score (with no reported subscale) on gynaecological problems
Wu 2014 Does not measure sexual dysfunction
RCT: randomised controlled trial
SD: sexual dysfunction
Characteristics of studies awaiting assessment [ordered by study ID]
Esplen 2014
Methods RCT
Participants Breast cancer survivors
Interventions Group therapy and guided imagery
Outcomes Sexual functioning
Notes Conference abstract of a study that has been completed - probably fits eligibility criteria - await full published version
Goetsch 2015
Methods RCT
Participants Breast cancer survivors
Interventions Analgesic liquid
Outcomes Penetration pain and sexual distress
Notes Conference abstract of study that has been completed - probably fits eligibility criteria - await full published version
Gremore 2014
Methods RCT
Participants Patients with head and neck cancer and their partners
Interventions Couple-based psychosocial intervention
Outcomes Not clear
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Gremore 2014 (Continued)
Notes Study in progress - unclear if eligible
Hickey 2015
Methods RCT
Participants Women with breast cancer
Interventions Lubricant for vaginal dryness
Outcomes Sexual discomfort
Notes Publication only of a conference abstract with preliminary findings
Jensen 2014
Methods RCT
Participants Patient undoing a radical cystectomy
Interventions Home-based exercises
Outcomes Quality of life measures
Notes Study in progress - unclear if eligible
Paterson 2015
Methods RCT
Participants Breast cancer survivors
Interventions Mindfulness-based stress reduction programme
Outcomes Sexual distress and body image disturbances




Interventions Web-based tailored intervention on psychosocial and lifestyle support
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Willems 2015 (Continued)
Outcomes Not stated
Notes Conference abstract of a study that is in progress - unclear if fits eligibility criteria
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Davis 2015
Trial name or title -
Methods RCT
Participants Women with breast cancer being treated with an aromatase inhibitor






Trial name or title Cancer Survivorship Intervention-Sexual Health (CSI-SH)
Methods Pilot RCT
Participants Female rectal and anal cancer survivors
Interventions 4 intervention sessions focused on different topics including education about the impact of treatment and
specific strategies for sexual health. The first 3 sessions were followed by booster telephone sessions to review
the strategies
Outcomes Assessments were at baseline and approximately 4 and 8 months post-baseline with measures of quality of life
(EORTC-QLQ-C30), Sexual Functioning (FSFI) and psychological wellbeing (e.g. Impact of Events Scale-
Revised: IES-R)
Starting date Not reported
Contact information duhamelk@mskcc.org
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Trial name or title Developing a Stepped Approach to improving sexual Function aFteR treatment fOr gyNaecological cancer
(SAFFRON)
Methods RCT
Participants Women treated for gynaecological cancer
Interventions The stepped care intervention will be developed over the first 6 months of the project. It will involve psycho-
logical therapies
Outcomes Sexual function




Trial name or title KIS Study: a study evaluating the effectiveness of an internet-based therapy program for sexuality and intimacy
problems in women treated for breast cancer
Methods RCT
Participants Breast cancer survivors
Interventions Behavioural: internet-based cognitive behavioural therapy
Outcomes Sexuality problems
Starting date December 2012
Contact information l.hummel@nki.nl
Notes ClinicalTrials.gov Identifier: NCT02091765
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NCT00459134 2015
Trial name or title L-Arginine supplements in treating women who are cancer survivors
Methods RCT
Participants Cancer survivors with sexual dysfunction
Interventions L-Arginine supplements
Outcomes Sexual function
Starting date 2007; study is reported to have been completed but no publication of results identified
Contact information Not provided
Notes -
NCT02091765 2015
Trial name or title KIS Study: a study evaluating the effectiveness of an Internet-based therapy program for sexuality and intimacy
problems in women treated for breast cancer. ID NCT02091765
Methods RCT
Participants Breast cancer survivors with intimacy problems
Interventions Internet-based cognitive behavioural therapy
Outcomes Sexuality problems
Starting date 2014
Contact information Neil K Aaronson n.aaronson@nki.nl
Notes -
Schofield 2013
Trial name or title The PeNTAGOn study (peer and nurse support trial to assist women in gynaecological oncology)
Methods RCT
Participants Women in gynaecological oncology receiving curative radiotherapy
Interventions A nurse- and peer-led support programme
Outcomes Primary outcome: psychological distress. Secondary outcomes: patient quality of life, symptomdistress, unmet
supportive care needs, preparation for treatment, psychosexual functioning and vaginal stenosis
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Schofield 2013 (Continued)
Starting date Not reported
Contact information Penelope.schofield@petermac.org
Notes -
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Barton 2007 scores for sexual functioning





5.69 (4.13 to 10.63)
3.40 (2.08 to 6.75)
6.87 (6.42 to 11.38)






9.38 (7.00 to 11.23)
4.71 (0.43 to 8.98)
9.33 (6.84 to 16.49)
11.04 (9.03 to 18.59)
Profile of Mood States Rx/placebo
Placebo/Rx
-0.55 (-3.77 to 2.67)
3.02 (-0.27 to 6.31)
1.07 (-1.89 to 4.03)
5.11 (2.16 to 8.07)




0.56 (-2.58 to 3.71)
2.76 (-0.52 to 6.04)
1.82 (-1.74 to 5.39)




Table 2. Aktas 2014 follow-up subscale scores for sexual function
Measure* Mean score at follow-up in intervention group Mean score at follow-up in control group
Sexual non-communication 5.14 (SD 2.07) 6.94 (SD 1.28)
Anorgasmia 8.83 (SD 1.79) 11.26 (SD 1.42)
Avoidance 6.34 (SD 3.13) 9.60 (SD 2.94)
Non-sensuality 7.43 (SD 3.09) 10.20 (SD 2.90)
Infrequency of sexual contact 6.03 (SD 1.58) 6.43 (SD 1.77)
Sexual dissatisfaction 7.0 (SD 2.82) 9.63 (SD 2.45)
Vaginismus 9.26 (SD 3.01) 12.17 (SD 3.31)
SD: standard deviation
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Table 3. Baucom 2009 follow-up scores for sexual functioning
Measure Mean score (SD) at follow-up in interven-
tion group
Mean score (SD) at follow-up in control
group
Sexual drive and relationship 13.00 (3.11) 9.80 (5.93)
Relationship satisfaction 39.71 (3.45) 40.20 (5.07)
Brief Symptom Inventory 6.71 (5.77) 15.80 (20.91)
Post-traumatic Growth Inventory 62.00 (29.10) 66.20 (35.73)
Functional Well-being FACT-B 3.22 (0.34) 2.89 (0.91)
Self-image Scale - self acceptance 21.29 (4.75) 19.20 (9.09)
Self-image Scale - partner acceptance 21.96 (2.27) 21.50 (4.79)
Brief Fatigue Inventory 2.98 (0.96) 3.22 (2.25)
Usual pain 2.29 (1.50) 2.40 (1.67)
Rotterdam Symptom Inventory 18.71 (2.36) 23.80 (9.81)
SD: standard deviation
Table 4. Classen 2013 follow-up subscale scores for sexual function
Measure Mean change from baseline score at fol-
low-up in intervention group
Mean change from baseline score at fol-
low-up in control group
Sexual function intention-to-treat* 2.54 (SD 9.59) 0.26 (SD 3.19)
Sexual function actively used* 3.82 (SD 9.43) 0.26 (SD 3.19)
Anxiety and depression** intention-to-
treat
0.63 (SD 4.39) 0.50 (SD 2.91)
Anxiety and depression** actively used 1.73 (SD 3.93) 0.50 (SD 2.91)
Intimacy*** intention-to-treat 0.19 (SD 1.33) -0.17 (SD 1.21)
Relationship*** intention-to-treat -0.04 (SD 0.68) -0.01 (SD 0.82)
Instrumental*** intention-to-treat -0.22 (SD 0.85) -0.10 (SD 1.26)
Intimacy*** 0.75 (SD 1.01) -0.17 (SD 1.21)
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Table 4. Classen 2013 follow-up subscale scores for sexual function (Continued)
Relationship*** -0.15 (SD 0.50) -0.01 (SD 0.82)
Instrumental** *-0.21 (SD 0.71) -0.10 (SD 1.26)
* Measured using the Female Sexual Distress Scale.** Measured using the Hospital Anxiety and Depression Scale. ***Measured using
the Illness Intrusiveness Ratings Scale.
SD: standard deviation
Table 5. Rowland 2009 follow-up subscale scores for sexual and psychological function
Measure Mean baseline (SD) and change score (SD)
at follow-up in intervention group
Mean baseline (SD) and change score (SD)
at follow-up in control group
Satisfaction with variety of sex 4.0 (1.1), 0.1 (1.2) 4.0 (1.0), -0.03 (1.0)
Satisfaction with sexual relationship 4.8 (1.1), 0.0 (1.5) 4.7 (1.4), -0.3 (1.3)*
Pain with sex 3.8 (2.0), 0.7 (1.9) 4.1 (1.9), -0.1 (1.7)
Pain interfering with pleasure 4.4 (1.7), 0.3 (1.4) 4.4 (1.7), 0.0 (1.1)
Improved comfort with sexuality* 3.3 (0.6) 3.1 (0.6)
Comfort about being touched 4.7 (1.6), 0.1 (1.4) 4.6 (1.6), -0.1 (1.2)
Comfort undressing 4.7 (1.7), 0.2 (1.9) 5.0 (1.4), -0.2 (1.8)
Comfort being nude 5.3 (1.4), 0.3 (1.3) 5.2 (1.4), -0.1 (1.6)
Impact of cancer on sex 2.6 (1.0), 0.1 (0.8) 2.4 (1.0), 0.2 (0.9)
Impact on relationship 50.9 (5.7), 1.1 (4.0) 51.0 (5.6), -1.3 (4.6)
Improved communication* 3.5 (0.7) 3.2 (0.7)
Mental health 80.8 (11.6), -0.7 (10.4) 82.6 (9.2), -3.8 (9.4)
* Measured at follow-up only
SD: standard deviation
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Table 6. Svensk 2009 follow-up scores
Measure Mean score (SD) at follow-up in interven-
tion group
Mean score (SD) at follow-up in control
group
Sexual function at 2 months 38.60 (24.88) 30.16 (28.20)
Sexual function at 6 months 34.21 (24.52) 28.33 (26.55)
Sexual enjoyment at 2 months 56.25 (26.44) 53.85 (25.60)
Sexual enjoyment at 6 months 69.05 (24.34) 72.22 (27.83)
Overall quality of life at 2 months 78.75 (14.68) 66.67 (22.82)
Overall quality of life at 6 months 85.00 (12.57) 67.50 (20.03)
Physical health at 2 months 68.75 (13.51) 61.39 (19.71)
Physical health at 6 months 74.82 (13.33) 63.93 (19.80)
Psychological health at 2 months 70.83 (15.29) 63.69 (15.87)
Psychological health at 6 months 73.96 (10.28) 69.38 (13.13)
Social relationships at 2 months 74.58 (14.43) 69.44 (15.66)
Social relationships at 6 months 77.50 (12.99) 71.67 (16.31)
Body image at 2 months 81.67 (24.57) 80.95 (20.77)
Body image at 6 months 91.25 (12.82) 83.33 (27.64)
Adverse effects at 2 months 14.76 (11.13) 20.33 (12.23)
Adverse effects at 6 months 10.24 (7.61) 14.97 (12.71)
Breast symptoms at 2 months 20.42 (16.10) 21.03 (14.58)
Breast symptoms at 6 months 17.08 (11.30) 20.63 (17.80)
Arm symptoms at 2 months 16.11 (21.77) 26.46 (29.71)
Arm symptoms at 6 months 15.56 (20.52) 18.52 (17.33)
Upset by hair loss at 2 months 11.11 (19.25) 50.00 (23.57)
Upset by hair loss at 6 months 25.00 (16.67) 50.00 (70.71)
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SD: standard deviation
A P P E N D I C E S
Appendix 1. Search strategies
Electronic database search terms as used in 2015 update
The search terms used reflected the three components to our research question:
• interventions for SD;
• SD variants;
• treatments for cancer.
The search terms are for both men and women; this is because initially we planned to include interventions for both sexes in one review.
The findings were only split when it became apparent that the number of trials would prevent timely completion of a review covering
both interventions for men and for women.
CENTRAL (The Cochrane Library)
#1 MeSH descriptor: [Alprostadil] explode all trees
#2 MeSH descriptor: [Papaverine] explode all trees
#3 MeSH descriptor: [Phentolamine] explode all trees
#4 MeSH descriptor: [Yohimbine] explode all trees
#5 MeSH descriptor: [Apomorphine] explode all trees
#6 MeSH descriptor: [Potassium Channels] explode all trees
#7 (alprostadil or androgel or Apomorphine or britaject or aromatase inhibitors or agonist of melancortin receptor or Adcirca or alpha
adrenoceptor agonist or alpha-2 adrenoceptor agonist or androgel or arginine or botox or botulinum toxin or bromocriptine or cialis
or dopaminergic agents or caverject or clomipramine or cyproheptadine or clonidine or delquamine or edex or hormone therapy
or Isoxsuprine or intracavernosal vasodilators or levitra or Lignocaine or l-arginine or lodenfil or Methitest or methyl testosterone
or midodrin or mianserin or moclobemide or mirtazapine or mianserin or moclobemide or ortho-gynest or ovestin or papaverine
or papaverine-phentolamine or phentolamine or parlodel or phentolamine or potassium channel openers or progestational agents or
premarin or prempro or prostins or Prostaglandins or prostaglandin E1 or pentoxifylline or potassium channels or Phosphodiesterase
Type 5 or PDE5i or penile suppository or reboxetine or sildenafil or tadalafil or tampovagan or topical or topical cream or vagifem or
vaginal cream or vaginal lubricant or vaginal or viagra or vasomax or Viagel or vardenafil or vasodilator or virilon or vasoactive or staxyn
or topical estrogen cream or trental or vasodilan or viridal or yohimbine or android or androgen therapy or testosterone or testosterone
cream or testosterone gel or testred):ti,ab,kw (Word variations have been searched)
#8 MeSH descriptor: [Testosterone] explode all trees
#9 MeSH descriptor: [Penile Implantation] explode all trees
#10 MeSH descriptor: [Penile Prosthesis] explode all trees
#11 MeSH descriptor: [Prosthesis Implantation] explode all trees
#12 (testosterone replacement or testosterone or venous constriction rings or vacuum device* or vacuum erect* or penile implant*
or penile arterialisation or venous litigation or prosthesis implant* or vacuum constriction device or vacuum therapy* or vibrat* or
vibrostimulation or electroejaculation or prolong ring*):ti,ab,kw (Word variations have been searched)
#13 MeSH descriptor: [Aromatase Inhibitors] explode all trees
#14 (vaginal dilator* or arginine or android or methyl testosterone or testosterone cream or vaginal lubricant or vaginal estradiol ring
or vaginal estradiol ring or vaginal estrogen ring or vaginal oestrogen ring or topical estrogen cream or vaginal cream or estrogen
replacement of ERT or estrogen replacement or aromatase inhibitors):ti,ab,kw (Word variations have been searched)
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#15 MeSH descriptor: [Estriol] explode all trees
#16 MeSH descriptor: [Estrogens, Conjugated (USP)] explode all trees
#17 MeSH descriptor: [Vaginal Creams, Foams, and Jellies] explode all trees
#18 MeSH descriptor: [Ginkgo biloba] explode all trees
#19 MeSH descriptor: [Pausinystalia] explode all trees
#20 MeSH descriptor: [Turnera] explode all trees
#21 MeSH descriptor: [Panax] explode all trees
#22 MeSH descriptor: [Hypericum] explode all trees
#23 MeSH descriptor: [Patient Education as Topic] explode all trees
#24 MeSH descriptor: [Psychological Techniques] explode all trees
#25 MeSH descriptor: [Psychotherapy] explode all trees
#26 MeSH descriptor: [Counseling] explode all trees
#27 MeSH descriptor: [Sex Counseling] explode all trees
#28 MeSH descriptor: [Cognitive Therapy] explode all trees
#29 (psychological intervention* or psycholog* or behavior* or behaviour* or cognitive behav* therapy or cognitive therap* or psy-
chotherap* or counsel* or sex therap* or patient educat* or behav* therapy or CBT or couple therap* or couple intervention or couple-
based or intimacy enhancing or mindfulness or patient education or psychological techniques or psychosexual or psychotherapy or
psycho-somatic or Rational emotive therap* or restoring intimacy or relaxation or relaxation therap* or relaxation training or psycho-
social or Sensual, body image or sex-counsel* or sexual communication or sexual rehabilitation or sexuality or self-esteem or self concept
or stress or psycho-education or sexual life reframing or coping skills or motivational counselling or anxiety management training or
marital therap* or group therap* or focal therap* or psychodynamic therap* or supportive therap* or psychoanalyses or interpersonal
therap* or individual therap* or problem solving or emotional support or hypnosis or bibliotherap* or sexual skills therap* or systematic
desensitization or hypnotherapy* or radical emotive therap* or psychodynamic or psychoeducational):ti,ab,kw (Word variations have
been searched)
#30 MeSH descriptor: [Phosphodiesterase 5 Inhibitors] explode all trees
#31 MeSH descriptor: [Vasodilator Agents] explode all trees
#32 (Phosphodiesterase Type 5 or PDE5i or adcirca or cialis or levitra or Viagra or vardenafil or sildenafil or tadalafil):ti,ab,kw (Word
variations have been searched)
#33 MeSH descriptor: [Aromatase Inhibitors] explode all trees
#34 MeSH descriptor: [Apomorphine] explode all trees
#35 (estriol or femprox):ti,ab,kw (Word variations have been searched)
#36 conjugated estrogens:ti,ab,kw (Word variations have been searched)
#37 estrogen ring:ti,ab,kw (Word variations have been searched)
#38 estrogen therapy:ti,ab,kw (Word variations have been searched)
#39 estrogen replacement:ti,ab,kw (Word variations have been searched)
#40 estradiol ring:ti,ab,kw (Word variations have been searched)
#41 vaginal oestrogen ring:ti,ab,kw (Word variations have been searched)
#42 estrogen cream:ti,ab,kw (Word variations have been searched)
#43 topical oestrogens:ti,ab,kw (Word variations have been searched)
#44 (oestrogen or epimestrol):ti,ab,kw (Word variations have been searched)
#45 (estradiol or oestrogenic steroids):ti,ab,kw (Word variations have been searched)
#46 (estrone or ethinyl estradiol or mestranol or quinestrol):ti,ab,kw (Word variations have been searched)
#47 (oestradiol or Dienestrol or estriol or estetrol):ti,ab,kw (Word variations have been searched)
#48 “selective oestrogen receptor modulator”:ti,ab,kw (Word variations have been searched)
#49 (clomiph or raloxifene or tamoxifen or toremife or clomid or clomifene or clomifert or serophene or raloxifene or keoxifene):
ti,ab,kw (Word variations have been searched)
#50 (evista or dimethylamine or novaldex or tomaxithen or soltamox or zitazonium or menerba):ti,ab,kw (Word variations have been
searched)
#51 (femarelle or toremifene or serm or bazedoxifene):ti,ab,kw (Word variations have been searched)
#52 ly-139481:ti,ab,kw (Word variations have been searched)
#53 ly-156758:ti,ab,kw (Word variations have been searched)
#54 MF-101:ti,ab,kw (Word variations have been searched)
#55 DT56a:ti,ab,kw (Word variations have been searched)
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#56 LY-117018:ti,ab,kw (Word variations have been searched)
#57 (arginine or acupuncture or DHEA or dehydroepiandrosterone or damiana or gingko or gingko bilboa or Hypericum or Panax
or pausinystalia or Turnera or turner diffusa or yohimbine or l-arginine, or pycnogeno, or viacreme or viagel or sensual or ginseng
or st john’s wort or complimentary medicine* or alternative medicine* or alternative therap* or alternative remed* or complimentary
therap* or complimentary remed*):ti,ab,kw (Word variations have been searched)
#58 (dilation or dilators or eros therap* or eros clitoral vacuum device or vaginal dilators or vibrator or vibrostimulation or mechanical
stretching of tissues or cock ring or electroejaculation or magnetic stimulation or penile implantation or penile prosthesis or penile
implant or penile arterialisation or penile vibratory stimulation or prosthesis implant* or prolong ring or muse or venous constriction
ring* or venous litigation or vacuum device* or vacuum constriction device* or vacuum therapy or vacuum pump or penile injection):
ti,ab,kw (Word variations have been searched)
#59 (kegel exercise* or lubricant* or lubrication or pelvic floor biofeedback or yoga or cream* or foam* or jellies or muscle relaxation or
vaginal exercise or physical exercise or olive oil or physiotherapy or weight lifting or physical training or pelvic floor muscle control or
self touch or penile rehabilitation or erectile rehabilitation orphysiotherap* or cavernous nerve regeneration, or sonic hedgehog or glial
growth factor 2 or GGF2 or magnetic stimulation or cavernous nerve stimulation or low-intensity extracorporeal shockwave therapy
or nerve stimulation):ti,ab,kw (Word variations have been searched)
#60 (alpha adrenoceptor agonist* or alpha adrenoceptor antagonist or midodrin or vasodilan or isoxsuprine or pentoxifylline or trental
or delquamine or pseudoephedrine or desipramine or cyproheptadine or lignocaine):ti,ab,kw (Word variations have been searched)
#61 MeSH descriptor: [Complementary Therapies] explode all trees
#62 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38
or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or
#57 or #58 or #59 or #60 or #61)
#63 MeSH descriptor: [Sexual Dysfunctions, Psychological] explode all trees
#64 MeSH descriptor: [Sexual Dysfunction, Physiological] explode all trees
#65 MeSH descriptor: [Erectile Dysfunction] explode all trees
#66 MeSH descriptor: [Lubrication] explode all trees
#67 MeSH descriptor: [Coitus] explode all trees
#68 MeSH descriptor: [Copulation] explode all trees
#69 ((sex* near/3 (dysfunct* or satisf* or problem* or symptom* or arousal* or activit*)) or orgasm or libido or lubricat* or impotence or
dyspareunia or hypoactive sexual desire disorder or sexual aversion or coitus or coition):ti,ab,kw (Word variations have been searched)
#70 (sexual intercourse or erectile dysfunction or erect* or sexual attraction or copulation or intimacy or procreat* or relations or sex or
sex act or sexual congress or sexual relation or arousal or penile erection or vaginal dryness or sexual pain or (pain* near/3 intercourse)
or (sex* near/3 pain*) or vaginismus or (sexual* near/2 wellbeing) or (sexual* near/2 well being) or sexual function* or (pain next
(urogential or vulval or vaginal or perineal or penile or testicular or ileostomy or colostomy or urostomy))):ti,ab,kw (Word variations
have been searched)
#71 (ejaculation dysfunction or premature ejaculation or early ejaculation or delayed ejaculation or retarded ejaculation or anejaculation
or painful ejaculation or retrograde ejaculation or anterograde ejaculation or inhibited ejaculation or erectile difficulty or erectile
dysfunction or loss of libido or lack of libido):ti,ab,kw (Word variations have been searched)
#72 #63 or #64 or #65 or #66 or #67 or #68 or #69 or #70 or #71
#73 MeSH descriptor: [Neoplasms] explode all trees
#74 MeSH descriptor: [Brachytherapy] explode all trees
#75 MeSH descriptor: [Radiotherapy, Conformal] explode all trees
#76 MeSH descriptor: [Radiotherapy, Adjuvant] explode all trees
#77 MeSH descriptor: [Chemotherapy, Adjuvant] explode all trees
#78 MeSH descriptor: [Mastectomy] explode all trees
#79 MeSH descriptor: [Prostatectomy] explode all trees
#80 (irradiat* or radiotherap* or chemotherap* or mastectom* or breast conserv* or prostatectom* or brachytherp or radiation or
prostectomy or oncology or excisional surgey or hysterectomy or radical surgery or vulvar surgery or cryotherpy or androgen suppression
or androgen deprivation or abdominoerineal resection or AP resection or APR or anterior resection or extralevator abdominoperineal
excision or ELAP or colostomy or mutilating surgery or vulval reconstruction or vaginal reconstruction or penile reconstruction or
breast reconstruction or breast implants):ti,ab,kw (Word variations have been searched)
#81 (neoplasm* or cancer* or carcinoma* or neoplasia* or adenocarcinoma* or tumor or malignan* or tumour*):ti,ab,kw (Word
variations have been searched)
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#82 (chemotherap* or mastectomy or breast conserv*or oophorectomy or hormone therapy or hormone treatment):ti,ab,kw (Word
variations have been searched)
#83 #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82







6. exp Potassium Channels/
7. (alprostadil or androgel or Apomorphine or britaject or aromatase inhibitors or agonist of melancortin receptor or Adcirca or alpha
adrenoceptor agonist or alpha-2 adrenoceptor agonist or androgel or arginine or botox or botulinum toxin or bromocriptine or cialis
or dopaminergic agents or caverject or clomipramine or cyproheptadine or clonidine or delquamine or edex or hormone therapy
or Isoxsuprine or intracavernosal vasodilators or levitra or Lignocaine or l-arginine or lodenfil or Methitest or methyl testosterone
or midodrin or mianserin or moclobemide or mirtazapine or mianserin or moclobemide or ortho-gynest or ovestin or papaverine
or papaverine-phentolamine or phentolamine or parlodel or phentolamine or potassium channel openers or progestational agents or
premarin or prempro or prostins or Prostaglandins or prostaglandin E1 or pentoxifylline or potassium channels or Phosphodiesterase
Type 5 or PDE5i or penile suppository or reboxetine or sildenafil or tadalafil or tampovagan or topical or topical cream or vagifem or
vaginal cream or vaginal lubricant or vaginal or viagra or vasomax or Viagel or vardenafil or vasodilator or virilon or vasoactive or staxyn
or topical estrogen cream or trental or vasodilan or viridal or yohimbine or android or androgen therapy or testosterone or testosterone
cream or testosterone gel or testred).tw.
8. exp Testosterone/
9. exp Penile Implantation/
10. exp Penile Prosthesis/
11. exp Prosthesis Implantation/
12. (testosterone replacement or testosterone or venous constriction rings or vacuum device* or vacuum erect* or penile implant*
or penile arterialisation or venous litigation or prosthesis implant* or vacuum constriction device or vacuum therapy* or vibrat* or
vibrostimulation or electroejaculation or prolong ring*).tw.
13. exp Aromatase Inhibitors/
14. (vaginal dilator* or arginine or android or methyl testosterone or testosterone cream or vaginal lubricant or vaginal estradiol ring
or vaginal estradiol ring or vaginal estrogen ring or vaginal oestrogen ring or topical estrogen cream or vaginal cream or estrogen
replacement of ERT or estrogen replacement or aromatase inhibitors).tw.
15. exp Estriol/
16. exp “Estrogens, Conjugated (USP)”/
17. exp “Vaginal Creams, Foams, and Jellies”/





23. exp Patient Education as Topic/
24. exp Psychological Techniques/
25. exp Psychotherapy/
26. exp Counseling/
27. exp Sex Counseling/
28. exp Cognitive Therapy/
29. (psychological intervention* or psycholog* or behavior* or behaviour* or cognitive behav* therapy or cognitive therap* or psy-
chotherap* or counsel* or sex therap* or patient educat* or behav* therapy or CBT or couple therap* or couple intervention or couple-
based or intimacy enhancing or mindfulness or patient education or psychological techniques or psychosexual or psychotherapy or
psycho-somatic or Rational emotive therap* or restoring intimacy or relaxation or relaxation therap* or relaxation training or psycho-
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social or Sensual, body image or sex-counsel* or sexual communication or sexual rehabilitation or sexuality or self-esteem or self concept
or stress or psycho-education or sexual life reframing or coping skills or motivational counselling or anxiety management training or
marital therap* or group therap* or focal therap* or psychodynamic therap* or supportive therap* or psychoanalyses or interpersonal
therap* or individual therap* or problem solving or emotional support or hypnosis or bibliotherap* or sexual skills therap* or systematic
desensitization or hypnotherapy* or radical emotive therap* or psychodynamic or psychoeducational).tw.
30. exp Phosphodiesterase 5 Inhibitors/
31. exp Vasodilator Agents/
32. (Phosphodiesterase Type 5 or PDE5i or adcirca or cialis or levitra or Viagra or vardenafil or sildenafil or tadalafil).tw.
33. exp Aromatase Inhibitors/
34. exp Apomorphine/






41. vaginal oestrogen ring.tw.
42. estrogen cream.tw.
43. topical oestrogens.tw.
44. (oestrogen or epimestrol).tw.
45. (estradiol or oestrogenic steroids).tw.
46. (estrone or ethinyl estradiol or mestranol or quinestrol).tw.
47. (oestradiol or Dienestrol or estriol or estetrol).tw.
48. selective oestrogen receptor modulators.tw.
49. (clomiph or raloxifene or tamoxifen or toremife or clomid or clomifene or clomifert or serophene or raloxifene or keoxifene).tw.
50. (evista or dimethylamine or novaldex or tomaxithen or soltamox or zitazonium or menerba).tw.






57. (arginine or acupuncture or DHEA or dehydroepiandrosterone or damiana or gingko or gingko bilboa or Hypericum or Panax
or pausinystalia or Turnera or turner diffusa or yohimbine or l-arginine, or pycnogeno, or viacreme or viagel or sensual or ginseng
or st john’s wort or complimentary medicine* or alternative medicine* or alternative therap* or alternative remed* or complimentary
therap* or complimentary remed*).tw.
58. (dilation or dilators or eros therap* or eros clitoral vacuum device or vaginal dilators or vibrator or vibrostimulation or mechanical
stretching of tissues or cock ring or electroejaculation or magnetic stimulation or penile implantation or penile prosthesis or penile
implant or penile arterialisation or penile vibratory stimulation or prosthesis implant* or prolong ring or muse or venous constriction
ring* or venous litigation or vacuum device* or vacuum constriction device* or vacuum therapy or vacuum pump or penile injection).tw.
59. (kegel exercise* or lubricant* or lubrication or pelvic floor biofeedback or yoga or cream* or foam* or jellies or muscle relaxation or
vaginal exercise or physical exercise or olive oil or physiotherapy or weight lifting or physical training or pelvic floor muscle control or
self touch or penile rehabilitation or erectile rehabilitation orphysiotherap* or cavernous nerve regeneration, or sonic hedgehog or glial
growth factor 2 or GGF2 or magnetic stimulation or cavernous nerve stimulation or low-intensity extracorporeal shockwave therapy
or nerve stimulation).tw.
60. (alpha adrenoceptor agonist* or alpha adrenoceptor antagonist or midodrin or vasodilan or isoxsuprine or pentoxifylline or trental
or delquamine or pseudoephedrine or desipramine or cyproheptadine or lignocaine).tw.
61. exp Complementary Therapies/
62. or/1-61
63. exp Sexual Dysfunctions, Psychological/ or exp Sexual Dysfunction, Physiological/
64. exp Erectile Dysfunction/
65. exp Lubrication/
66. exp Coitus/
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67. exp Copulation/
68. ((sex* adj3 (dysfunct* or satisf* or problem* or symptom* or arousal* or activit*)) or orgasm or libido or lubricat* or impotence or
dyspareunia or hypoactive sexual desire disorder or sexual aversion or coitus or coition).tw.
69. (sexual intercourse or erectile dysfunction or erect* or sexual attraction or copulation or intimacy or procreat* or relations or sex or
sex act or sexual congress or sexual relation or arousal or penile erection or vaginal dryness or sexual pain or (pain* adj3 intercourse) or
(sex* adj3 pain*) or vaginismus or (sexual* adj2 wellbeing) or (sexual* adj2 well being) or sexual function* or (pain adj (urogential or
vulval or vaginal or perineal or penile or testicular or ileostomy or colostomy or urostomy))).tw.
70. (ejaculation dysfunction or premature ejaculation or early ejaculation or delayed ejaculation or retarded ejaculation or anejaculation
or painful ejaculation or retrograde ejaculation or anterograde ejaculation or inhibited ejaculation or erectile difficulty or erectile




74. exp Radiotherapy, Conformal/
75. exp Radiotherapy, Adjuvant/
76. exp Chemotherapy, Adjuvant/
77. exp Mastectomy/
78. exp Prostatectomy/
79. (irradiat* or radiotherap* or chemotherap* or mastectom* or breast conserv* or prostatectom* or brachytherp or radiation or
prostectomy or oncology or excisional surgey or hysterectomy or radical surgery or vulvar surgery or cryotherpy or androgen suppression
or androgen deprivation or abdominoerineal resection or AP resection or APR or anterior resection or extralevator abdominoperineal
excision or ELAP or colostomy or mutilating surgery or vulval reconstruction or vaginal reconstruction or penile reconstruction or
breast reconstruction or breast implants).tw.
80. (neoplasm* or cancer* or carcinoma* or neoplasia* or adenocarcinoma* or tumor or malignan* or tumour*).tw.
81. (chemotherap* or mastectomy or breast conserv*or oophorectomy or hormone therapy or hormone treatment).tw.
82. or/72-81
83. 62 and 71 and 82
84. randomized controlled trial.pt.







92. exp animals/ not humans.sh.
93. 91 not 92







6. exp Potassium Channels/
7. (alprostadil or androgel or Apomorphine or britaject or aromatase inhibitors or agonist of melancortin receptor or Adcirca or alpha
adrenoceptor agonist or alpha-2 adrenoceptor agonist or androgel or arginine or botox or botulinum toxin or bromocriptine or cialis
or dopaminergic agents or caverject or clomipramine or cyproheptadine or clonidine or delquamine or edex or hormone therapy
or Isoxsuprine or intracavernosal vasodilators or levitra or Lignocaine or l-arginine or lodenfil or Methitest or methyl testosterone
or midodrin or mianserin or moclobemide or mirtazapine or mianserin or moclobemide or ortho-gynest or ovestin or papaverine
or papaverine-phentolamine or phentolamine or parlodel or phentolamine or potassium channel openers or progestational agents or
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premarin or prempro or prostins or Prostaglandins or prostaglandin E1 or pentoxifylline or potassium channels or Phosphodiesterase
Type 5 or PDE5i or penile suppository or reboxetine or sildenafil or tadalafil or tampovagan or topical or topical cream or vagifem or
vaginal cream or vaginal lubricant or vaginal or viagra or vasomax or Viagel or vardenafil or vasodilator or virilon or vasoactive or staxyn
or topical estrogen cream or trental or vasodilan or viridal or yohimbine or android or androgen therapy or testosterone or testosterone
cream or testosterone gel or testred).tw.
8. exp Testosterone/
9. exp Penile Implantation/
10. exp Penile Prosthesis/
11. exp Prosthesis Implantation/
12. (testosterone replacement or testosterone or venous constriction rings or vacuum device* or vacuum erect* or penile implant*
or penile arterialisation or venous litigation or prosthesis implant* or vacuum constriction device or vacuum therapy* or vibrat* or
vibrostimulation or electroejaculation or prolong ring*).tw.
13. exp Aromatase Inhibitors/
14. (vaginal dilator* or arginine or android or methyl testosterone or testosterone cream or vaginal lubricant or vaginal estradiol ring
or vaginal estradiol ring or vaginal estrogen ring or vaginal oestrogen ring or topical estrogen cream or vaginal cream or estrogen
replacement of ERT or estrogen replacement or aromatase inhibitors).tw.
15. exp Estriol/
16. exp “Estrogens, Conjugated (USP)”/
17. exp “Vaginal Creams, Foams, and Jellies”/





23. exp Patient Education as Topic/
24. exp Psychological Techniques/
25. exp Psychotherapy/
26. exp Counseling/
27. exp Sex Counseling/
28. exp Cognitive Therapy/
29. (psychological intervention* or psycholog* or behavior* or behaviour* or cognitive behav* therapy or cognitive therap* or psy-
chotherap* or counsel* or sex therap* or patient educat* or behav* therapy or CBT or couple therap* or couple intervention or couple-
based or intimacy enhancing or mindfulness or patient education or psychological techniques or psychosexual or psychotherapy or
psycho-somatic or Rational emotive therap* or restoring intimacy or relaxation or relaxation therap* or relaxation training or psycho-
social or Sensual, body image or sex-counsel* or sexual communication or sexual rehabilitation or sexuality or self-esteem or self concept
or stress or psycho-education or sexual life reframing or coping skills or motivational counselling or anxiety management training or
marital therap* or group therap* or focal therap* or psychodynamic therap* or supportive therap* or psychoanalyses or interpersonal
therap* or individual therap* or problem solving or emotional support or hypnosis or bibliotherap* or sexual skills therap* or systematic
desensitization or hypnotherapy* or radical emotive therap* or psychodynamic or psychoeducational).tw.
30. exp Phosphodiesterase 5 Inhibitors/
31. exp Vasodilator Agents/
32. (Phosphodiesterase Type 5 or PDE5i or adcirca or cialis or levitra or Viagra or vardenafil or sildenafil or tadalafil).tw.
33. exp Aromatase Inhibitors/
34. exp Apomorphine/






41. vaginal oestrogen ring.tw.
42. estrogen cream.tw.
43. topical oestrogens.tw.
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44. (oestrogen or epimestrol).tw.
45. (estradiol or oestrogenic steroids).tw.
46. (estrone or ethinyl estradiol or mestranol or quinestrol).tw.
47. (oestradiol or Dienestrol or estriol or estetrol).tw.
48. selective oestrogen receptor modulators.tw.
49. (clomiph or raloxifene or tamoxifen or toremife or clomid or clomifene or clomifert or serophene or raloxifene or keoxifene).tw.
50. (evista or dimethylamine or novaldex or tomaxithen or soltamox or zitazonium or menerba).tw.






57. (arginine or acupuncture or DHEA or dehydroepiandrosterone or damiana or gingko or gingko bilboa or Hypericum or Panax
or pausinystalia or Turnera or turner diffusa or yohimbine or l-arginine, or pycnogeno, or viacreme or viagel or sensual or ginseng
or st john’s wort or complimentary medicine* or alternative medicine* or alternative therap* or alternative remed* or complimentary
therap* or complimentary remed*).tw.
58. (dilation or dilators or eros therap* or eros clitoral vacuum device or vaginal dilators or vibrator or vibrostimulation or mechanical
stretching of tissues or cock ring or electroejaculation or magnetic stimulation or penile implantation or penile prosthesis or penile
implant or penile arterialisation or penile vibratory stimulation or prosthesis implant* or prolong ring or muse or venous constriction
ring* or venous litigation or vacuum device* or vacuum constriction device* or vacuum therapy or vacuum pump or penile injection).tw.
59. (kegel exercise* or lubricant* or lubrication or pelvic floor biofeedback or yoga or cream* or foam* or jellies or muscle relaxation or
vaginal exercise or physical exercise or olive oil or physiotherapy or weight lifting or physical training or pelvic floor muscle control or
self touch or penile rehabilitation or erectile rehabilitation orphysiotherap* or cavernous nerve regeneration, or sonic hedgehog or glial
growth factor 2 or GGF2 or magnetic stimulation or cavernous nerve stimulation or low-intensity extracorporeal shockwave therapy
or nerve stimulation).tw.
60. (alpha adrenoceptor agonist* or alpha adrenoceptor antagonist or midodrin or vasodilan or isoxsuprine or pentoxifylline or trental
or delquamine or pseudoephedrine or desipramine or cyproheptadine or lignocaine).tw.
61. exp Complementary Therapies/
62. or/1-61
63. exp Sexual Dysfunctions, Psychological/ or exp Sexual Dysfunction, Physiological/




68. ((sex* adj3 (dysfunct* or satisf* or problem* or symptom* or arousal* or activit*)) or orgasm or libido or lubricat* or impotence or
dyspareunia or hypoactive sexual desire disorder or sexual aversion or coitus or coition).tw.
69. (sexual intercourse or erectile dysfunction or erect* or sexual attraction or copulation or intimacy or procreat* or relations or sex or
sex act or sexual congress or sexual relation or arousal or penile erection or vaginal dryness or sexual pain or (pain* adj3 intercourse) or
(sex* adj3 pain*) or vaginismus or (sexual* adj2 wellbeing) or (sexual* adj2 well being) or sexual function* or (pain adj (urogential or
vulval or vaginal or perineal or penile or testicular or ileostomy or colostomy or urostomy))).tw.
70. (ejaculation dysfunction or premature ejaculation or early ejaculation or delayed ejaculation or retarded ejaculation or anejaculation
or painful ejaculation or retrograde ejaculation or anterograde ejaculation or inhibited ejaculation or erectile difficulty or erectile




74. exp Radiotherapy, Conformal/
75. exp Radiotherapy, Adjuvant/
76. exp Chemotherapy, Adjuvant/
77. exp Mastectomy/
78. exp Prostatectomy/
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79. (irradiat* or radiotherap* or chemotherap* or mastectom* or breast conserv* or prostatectom* or brachytherp or radiation or
prostectomy or oncology or excisional surgey or hysterectomy or radical surgery or vulvar surgery or cryotherpy or androgen suppression
or androgen deprivation or abdominoerineal resection or AP resection or APR or anterior resection or extralevator abdominoperineal
excision or ELAP or colostomy or mutilating surgery or vulval reconstruction or vaginal reconstruction or penile reconstruction or
breast reconstruction or breast implants).tw.
80. (neoplasm* or cancer* or carcinoma* or neoplasia* or adenocarcinoma* or tumor or malignan* or tumour*).tw.
81. (chemotherap* or mastectomy or breast conserv*or oophorectomy or hormone therapy or hormone treatment).tw.
82. or/72-81







90. (doubl$ adj blind$).tw.






97. Randomized Controlled Trial/
98. Single Blind Procedure/
99. or/84-98
100. (animal/ or nonhuman/) not human/
101. 99 not 100





4. (alprostadil or androgel or Apomorphine or britaject or aromatase inhibitors or agonist of melancortin receptor or Adcirca or alpha
adrenoceptor agonist or alpha-2 adrenoceptor agonist or androgel or arginine or botox or botulinum toxin or bromocriptine or cialis
or dopaminergic agents or caverject or clomipramine or cyproheptadine or clonidine or delquamine or edex or hormone therapy
or Isoxsuprine or intracavernosal vasodilators or levitra or Lignocaine or l-arginine or lodenfil or Methitest or methyl testosterone
or midodrin or mianserin or moclobemide or mirtazapine or mianserin or moclobemide or ortho-gynest or ovestin or papaverine
or papaverine-phentolamine or phentolamine or parlodel or phentolamine or potassium channel openers or progestational agents or
premarin or prempro or prostins or Prostaglandins or prostaglandin E1 or pentoxifylline or potassium channels or Phosphodiesterase
Type 5 or PDE5i or penile suppository or reboxetine or sildenafil or tadalafil or tampovagan or topical or topical cream or vagifem or
vaginal cream or vaginal lubricant or vaginal or viagra or vasomax or Viagel or vardenafil or vasodilator or virilon or vasoactive or staxyn
or topical estrogen cream or trental or vasodilan or viridal or yohimbine or android or androgen therapy or testosterone or testosterone
cream or testosterone gel or testred).tw.
5. exp Testosterone/
6. (testosterone replacement or testosterone or venous constriction rings or vacuum device* or vacuum erect* or penile implant*
or penile arterialisation or venous litigation or prosthesis implant* or vacuum constriction device or vacuum therapy* or vibrat* or
vibrostimulation or electroejaculation or prolong ring*).tw.
7. (vaginal dilator* or arginine or android or methyl testosterone or testosterone cream or vaginal lubricant or vaginal estradiol ring
or vaginal estradiol ring or vaginal estrogen ring or vaginal oestrogen ring or topical estrogen cream or vaginal cream or estrogen
replacement of ERT or estrogen replacement or aromatase inhibitors).tw.
8. exp Hypericum/
64Interventions for sexual dysfunction following treatments for cancer in women (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
9. exp Psychotherapy/
10. exp Counseling/
11. exp Cognitive Therapy/
12. (psychological intervention* or psycholog* or behavior* or behaviour* or cognitive behav* therapy or cognitive therap* or psy-
chotherap* or counsel* or sex therap* or patient educat* or behav* therapy or CBT or couple therap* or couple intervention or couple-
based or intimacy enhancing or mindfulness or patient education or psychological techniques or psychosexual or psychotherapy or
psycho-somatic or Rational emotive therap* or restoring intimacy or relaxation or relaxation therap* or relaxation training or psycho-
social or Sensual, body image or sex-counsel* or sexual communication or sexual rehabilitation or sexuality or self-esteem or self concept
or stress or psycho-education or sexual life reframing or coping skills or motivational counselling or anxiety management training or
marital therap* or group therap* or focal therap* or psychodynamic therap* or supportive therap* or psychoanalyses or interpersonal
therap* or individual therap* or problem solving or emotional support or hypnosis or bibliotherap* or sexual skills therap* or systematic
desensitization or hypnotherapy* or radical emotive therap* or psychodynamic or psychoeducational).tw.
13. (Phosphodiesterase Type 5 or PDE5i or adcirca or cialis or levitra or Viagra or vardenafil or sildenafil or tadalafil).tw.
14. exp Aromatase Inhibitors/
15. exp Apomorphine/





21. vaginal oestrogen ring.tw.
22. estrogen cream.tw.
23. topical oestrogens.tw.
24. (oestrogen or epimestrol).tw.
25. (estradiol or oestrogenic steroids).tw.
26. (estrone or ethinyl estradiol or mestranol or quinestrol).tw.
27. (oestradiol or Dienestrol or estriol or estetrol).tw.
28. selective oestrogen receptor modulators.tw.
29. (clomiph or raloxifene or tamoxifen or toremife or clomid or clomifene or clomifert or serophene or raloxifene or keoxifene).tw.
30. (evista or dimethylamine or novaldex or tomaxithen or soltamox or zitazonium or menerba).tw.






37. (arginine or acupuncture or DHEA or dehydroepiandrosterone or damiana or gingko or gingko bilboa or Hypericum or Panax
or pausinystalia or Turnera or turner diffusa or yohimbine or l-arginine, or pycnogeno, or viacreme or viagel or sensual or ginseng
or st john’s wort or complimentary medicine* or alternative medicine* or alternative therap* or alternative remed* or complimentary
therap* or complimentary remed*).tw.
38. (dilation or dilators or eros therap* or eros clitoral vacuum device or vaginal dilators or vibrator or vibrostimulation or mechanical
stretching of tissues or cock ring or electroejaculation or magnetic stimulation or penile implantation or penile prosthesis or penile
implant or penile arterialisation or penile vibratory stimulation or prosthesis implant* or prolong ring or muse or venous constriction
ring* or venous litigation or vacuum device* or vacuum constriction device* or vacuum therapy or vacuum pump or penile injection).tw.
39. (kegel exercise* or lubricant* or lubrication or pelvic floor biofeedback or yoga or cream* or foam* or jellies or muscle relaxation or
vaginal exercise or physical exercise or olive oil or physiotherapy or weight lifting or physical training or pelvic floor muscle control or
self touch or penile rehabilitation or erectile rehabilitation orphysiotherap* or cavernous nerve regeneration, or sonic hedgehog or glial
growth factor 2 or GGF2 or magnetic stimulation or cavernous nerve stimulation or low-intensity extracorporeal shockwave therapy
or nerve stimulation).tw.
40. (alpha adrenoceptor agonist* or alpha adrenoceptor antagonist or midodrin or vasodilan or isoxsuprine or pentoxifylline or trental
or delquamine or pseudoephedrine or desipramine or cyproheptadine or lignocaine).tw.
41. exp Alternative Medicine/
42. exp Sexual Function Disturbances/
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43. exp Erectile Dysfunction/
44. exp Coitus/
45. exp Copulation/
46. ((sex* adj3 (dysfunct* or satisf* or problem* or symptom* or arousal* or activit*)) or orgasm or libido or lubricat* or impotence or
dyspareunia or hypoactive sexual desire disorder or sexual aversion or coitus or coition).tw.
47. (sexual intercourse or erectile dysfunction or erect* or sexual attraction or copulation or intimacy or procreat* or relations or sex or
sex act or sexual congress or sexual relation or arousal or penile erection or vaginal dryness or sexual pain or (pain* adj3 intercourse) or
(sex* adj3 pain*) or vaginismus or (sexual* adj2 wellbeing) or (sexual* adj2 well being) or sexual function* or (pain adj (urogential or
vulval or vaginal or perineal or penile or testicular or ileostomy or colostomy or urostomy))).tw.
48. (ejaculation dysfunction or premature ejaculation or early ejaculation or delayed ejaculation or retarded ejaculation or anejaculation
or painful ejaculation or retrograde ejaculation or anterograde ejaculation or inhibited ejaculation or erectile difficulty or erectile
dysfunction or loss of libido or lack of libido).tw.
49. exp Neoplasms/
50. exp Brachytherapy/
51. exp Radiation Therapy/
52. exp Chemotherapy/
53. exp Mastectomy/
54. (irradiat* or radiotherap* or chemotherap* or mastectom* or breast conserv* or prostatectom* or brachytherp or radiation or
prostectomy or oncology or excisional surgey or hysterectomy or radical surgery or vulvar surgery or cryotherpy or androgen suppression
or androgen deprivation or abdominoerineal resection or AP resection or APR or anterior resection or extralevator abdominoperineal
excision or ELAP or colostomy or mutilating surgery or vulval reconstruction or vaginal reconstruction or penile reconstruction or
breast reconstruction or breast implants).tw.
55. (neoplasm* or cancer* or carcinoma* or neoplasia* or adenocarcinoma* or tumor or malignan* or tumour*).tw.
56. (chemotherap* or mastectomy or breast conserv*or oophorectomy or hormone therapy or hormone treatment).tw.
57. clinical trials/
58. (randomis* or randomiz*).tw.
59. (random$ adj3 (allocat$ or assign$)).tw.
60. ((clinic$ or control$) adj trial$).tw.
61. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.





67. exp program evaluation/
68. treatment effectiveness evaluation/





74. 70 and 71 and 72 and 73
AMED (OVID)
(No RCT filter added)
1. (alprostadil or androgel or Apomorphine or britaject or aromatase inhibitors or agonist of melancortin receptor or Adcirca or alpha
adrenoceptor agonist or alpha-2 adrenoceptor agonist or androgel or arginine or botox or botulinum toxin or bromocriptine or cialis
or dopaminergic agents or caverject or clomipramine or cyproheptadine or clonidine or delquamine or edex or hormone therapy
or Isoxsuprine or intracavernosal vasodilators or levitra or Lignocaine or l-arginine or lodenfil or Methitest or methyl testosterone
or midodrin or mianserin or moclobemide or mirtazapine or mianserin or moclobemide or ortho-gynest or ovestin or papaverine
or papaverine-phentolamine or phentolamine or parlodel or phentolamine or potassium channel openers or progestational agents or
premarin or prempro or prostins or Prostaglandins or prostaglandin E1 or pentoxifylline or potassium channels or Phosphodiesterase
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Type 5 or PDE5i or penile suppository or reboxetine or sildenafil or tadalafil or tampovagan or topical or topical cream or vagifem or
vaginal cream or vaginal lubricant or vaginal or viagra or vasomax or Viagel or vardenafil or vasodilator or virilon or vasoactive or staxyn
or topical estrogen cream or trental or vasodilan or viridal or yohimbine or android or androgen therapy or testosterone or testosterone
cream or testosterone gel or testred).tw.
2. exp Testosterone/
3. (testosterone replacement or testosterone or venous constriction rings or vacuum device* or vacuum erect* or penile implant*
or penile arterialisation or venous litigation or prosthesis implant* or vacuum constriction device or vacuum therapy* or vibrat* or
vibrostimulation or electroejaculation or prolong ring*).tw.
4. (vaginal dilator* or arginine or android or methyl testosterone or testosterone cream or vaginal lubricant or vaginal estradiol ring
or vaginal estradiol ring or vaginal estrogen ring or vaginal oestrogen ring or topical estrogen cream or vaginal cream or estrogen
replacement of ERT or estrogen replacement or aromatase inhibitors).tw.





10. exp Sex Counseling/
11. exp Cognitive Therapy/
12. (psychological intervention* or psycholog* or behavior* or behaviour* or cognitive behav* therapy or cognitive therap* or psy-
chotherap* or counsel* or sex therap* or patient educat* or behav* therapy or CBT or couple therap* or couple intervention or couple-
based or intimacy enhancing or mindfulness or patient education or psychological techniques or psychosexual or psychotherapy or
psycho-somatic or Rational emotive therap* or restoring intimacy or relaxation or relaxation therap* or relaxation training or psycho-
social or Sensual, body image or sex-counsel* or sexual communication or sexual rehabilitation or sexuality or self-esteem or self concept
or stress or psycho-education or sexual life reframing or coping skills or motivational counselling or anxiety management training or
marital therap* or group therap* or focal therap* or psychodynamic therap* or supportive therap* or psychoanalyses or interpersonal
therap* or individual therap* or problem solving or emotional support or hypnosis or bibliotherap* or sexual skills therap* or systematic
desensitization or hypnotherapy* or radical emotive therap* or psychodynamic or psychoeducational).tw.
13. exp Vasodilator Agents/
14. (Phosphodiesterase Type 5 or PDE5i or adcirca or cialis or levitra or Viagra or vardenafil or sildenafil or tadalafil).tw.






21. vaginal oestrogen ring.tw.
22. estrogen cream.tw.
23. topical oestrogens.tw.
24. (oestrogen or epimestrol).tw.
25. (estradiol or oestrogenic steroids).tw.
26. (estrone or ethinyl estradiol or mestranol or quinestrol).tw.
27. (oestradiol or Dienestrol or estriol or estetrol).tw.
28. selective oestrogen receptor modulators.tw.
29. (clomiph or raloxifene or tamoxifen or toremife or clomid or clomifene or clomifert or serophene or raloxifene or keoxifene).tw.
30. (evista or dimethylamine or novaldex or tomaxithen or soltamox or zitazonium or menerba).tw.






37. (arginine or acupuncture or DHEA or dehydroepiandrosterone or damiana or gingko or gingko bilboa or Hypericum or Panax
or pausinystalia or Turnera or turner diffusa or yohimbine or l-arginine, or pycnogeno, or viacreme or viagel or sensual or ginseng
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or st john’s wort or complimentary medicine* or alternative medicine* or alternative therap* or alternative remed* or complimentary
therap* or complimentary remed*).tw.
38. (dilation or dilators or eros therap* or eros clitoral vacuum device or vaginal dilators or vibrator or vibrostimulation or mechanical
stretching of tissues or cock ring or electroejaculation or magnetic stimulation or penile implantation or penile prosthesis or penile
implant or penile arterialisation or penile vibratory stimulation or prosthesis implant* or prolong ring or muse or venous constriction
ring* or venous litigation or vacuum device* or vacuum constriction device* or vacuum therapy or vacuum pump or penile injection).tw.
39. (kegel exercise* or lubricant* or lubrication or pelvic floor biofeedback or yoga or cream* or foam* or jellies or muscle relaxation or
vaginal exercise or physical exercise or olive oil or physiotherapy or weight lifting or physical training or pelvic floor muscle control or
self touch or penile rehabilitation or erectile rehabilitation orphysiotherap* or cavernous nerve regeneration, or sonic hedgehog or glial
growth factor 2 or GGF2 or magnetic stimulation or cavernous nerve stimulation or low-intensity extracorporeal shockwave therapy
or nerve stimulation).tw.
40. (alpha adrenoceptor agonist* or alpha adrenoceptor antagonist or midodrin or vasodilan or isoxsuprine or pentoxifylline or trental
or delquamine or pseudoephedrine or desipramine or cyproheptadine or lignocaine).tw.
41. exp Complementary Therapies/
42. exp Sexual Dysfunctions, Psychological/ or exp Sexual Dysfunction, Physiological/




47. ((sex* adj3 (dysfunct* or satisf* or problem* or symptom* or arousal* or activit*)) or orgasm or libido or lubricat* or impotence or
dyspareunia or hypoactive sexual desire disorder or sexual aversion or coitus or coition).tw.
48. (sexual intercourse or erectile dysfunction or erect* or sexual attraction or copulation or intimacy or procreat* or relations or sex or
sex act or sexual congress or sexual relation or arousal or penile erection or vaginal dryness or sexual pain or (pain* adj3 intercourse) or
(sex* adj3 pain*) or vaginismus or (sexual* adj2 wellbeing) or (sexual* adj2 well being) or sexual function* or (pain adj (urogential or
vulval or vaginal or perineal or penile or testicular or ileostomy or colostomy or urostomy))).tw.
49. (ejaculation dysfunction or premature ejaculation or early ejaculation or delayed ejaculation or retarded ejaculation or anejaculation
or painful ejaculation or retrograde ejaculation or anterograde ejaculation or inhibited ejaculation or erectile difficulty or erectile






55. (irradiat* or radiotherap* or chemotherap* or mastectom* or breast conserv* or prostatectom* or brachytherp or radiation or
prostectomy or oncology or excisional surgey or hysterectomy or radical surgery or vulvar surgery or cryotherpy or androgen suppression
or androgen deprivation or abdominoerineal resection or AP resection or APR or anterior resection or extralevator abdominoperineal
excision or ELAP or colostomy or mutilating surgery or vulval reconstruction or vaginal reconstruction or penile reconstruction or
breast reconstruction or breast implants).tw.
56. (neoplasm* or cancer* or carcinoma* or neoplasia* or adenocarcinoma* or tumor or malignan* or tumour*).tw.
57. (chemotherap* or mastectomy or breast conserv*or oophorectomy or hormone therapy or hormone treatment).tw.
58. or/1-41
59. or/51-57
60. 50 and 58 and 59
CINAHL (EBSCO)
S91 S81 AND S90
S90 S82 OR S83 OR S84 OR S85 OR S86 OR S87 OR S88 OR S89
S89 (allocat* random*)
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S84 (MH “Random Assignment”)
S83 (Randomi?ed control* trial*)
S82 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or
(singl* mask* )
S81 S60 AND S68 AND S79
S80 S60 AND S68 AND S79
S79 S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78 Search modes - Boolean/Phrase
Interface - EBSCOhost Research
Databases
S78 (neoplasm* or cancer* or carcinoma* or neoplasia* or adenocarcinoma* or tumor or malignan* or tumour*)
S77 (chemotherap* or mastectomy or breast conserv*or oophorectomy or hormone therapy or hormone treatment)
S76 (irradiat* or radiotherap* or chemotherap* or mastectom* or breast conserv* or prostatectom* or brachytherp or radiation or
prostectomy
or oncology or excisional surgey or hysterectomy or radical surgery or vulvar surgery or cryotherpy or androgen suppression or androgen
deprivation or abdominoerineal resection or AP resection or APR or anterior resection or extralevator abdominoperineal excision or
ELAP or





S73 (MH “Chemotherapy, Adjuvant”)
S72 (MH “Radiotherapy, Adjuvant”)
S71 (MH “Radiotherapy, Conformal”)
S70 (MH “Brachytherapy”)
S69 (MH “Neoplasms+”)
S68 S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR S67
S67 (ejaculation dysfunction or premature ejaculation or early ejaculation or delayed ejaculation or retarded ejaculation or anejaculation
or
painful ejaculationor retrograde ejaculationor anterograde ejaculationor inhibited ejaculationor erectile difficulty or erectile dysfunction
or loss of libido or lack of libido)
S66 (pain N1 (urogential or vulval or vaginal or perineal or penile or testicular or ileostomy or colostomy or urostomy))
S65 ((pain* N3 intercourse) or (sex* N3 pain*) or vaginismus or (sexual* N2 wellbeing) or (sexual* N2 well being) or( sexual
function*))
S64 ((sex* N3 (dysfunct* or satisf* or problem* or symptom* or arousal* or activit*)) or orgasm or libido or lubricat* or impotence or
dyspareunia or hypoactive sexual desire disorder or sexual aversion or coitus or coition)
S63 (MH “Coitus”)
S62 (MH “Impotence”)
S61 (MH “Psychosexual Disorders+”)
S60 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR
S17 OR S18 OR S19 OR S20 OR S21 OR
S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR
S37 OR S38 OR S39 OR S40 OR S41 OR S42
OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57
OR S58 OR
S59 (MH “Alternative Therapies+”)
S58 (alpha adrenoceptor agonist* or alpha adrenoceptor antagonist or midodrin or vasodilan or isoxsuprine or pentoxifylline or trental
or
delquamine or pseudoephedrine or desipramine or cyproheptadine or lignocaine)
S57 (kegel exercise* or lubricant* or lubrication or pelvic floor biofeedback or yoga or cream* or foam* or jellies or muscle relaxation or
vaginal exercise or physical exercise or olive oil or physiotherapy or weight lifting or physical training or pelvic floor muscle control or
self
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touch or penile rehabilitation or erectile rehabilitation orphysiotherap* or cavernous nerve regeneration, or sonic hedgehog or glial
growth
factor 2 or GGF2 or magnetic stimulation or cavernous nerve stimulation or low-intensity extracorporeal shockwave therapy or nerve
stimulation)
S56 (dilation or dilators or eros therap* or eros clitoral vacuum device or vaginal dilators or vibrator or vibrostimulation or mechanical
stretching of tissues or cock ring or electroejaculation or magnetic stimulation or penile implantation or penile prosthesis or penile
implant or
penile arterialisation or penile vibratory stimulation or prosthesis implant* or prolong ring or muse or venous constriction ring* or
venous
litigation or vacuum device* or vacuum constriction device* or vacuum therapy or vacuum pump or penile injection)
S55 (arginine or acupuncture or DHEA or dehydroepiandrosterone or damiana or gingko or gingko bilboa or Hypericum or Panax or
pausinystalia
or Turnera or turner diffusa or yohimbine or l-arginine, or pycnogeno, or viacreme or viagel or sensual or ginseng or st john’s wort or







S49 (femarelle or toremifene or serm or bazedoxifene)
S48 (evista or dimethylamine or novaldex or tomaxithen or soltamox or zitazonium or menerba)
S47 (clomiph or raloxifene or tamoxifen or toremife or clomid or clomifene or clomifert or serophene or raloxifene or keoxifene)
S46 “selective oestrogen receptor modulators”
S45 (oestradiol or Dienestrol or estriol or estetrol)
S44 (estrone or ethinyl estradiol or mestranol or quinestrol)
S43 (estradiol or oestrogenic steroids)
S42 (oestrogen or epimestrol)
S41 topical oestrogens
S40 estrogen cream
S39 vaginal oestrogen ring






S32 (estriol or femprox)
S31 (MH “Apomorphine”)
S30 (MH “Aromatase Inhibitors+”)
S29 (Phosphodiesterase Type 5 or PDE5i or adcirca or cialis or levitra or Viagra or vardenafil or sildenafil or tadalafil)
S28 Vasodilator Agents
S27 (MH “Phosphodiesterase Inhibitors+”)
S26 (psychological intervention* or psycholog* or behavior* or behaviour* or cognitive behav* therapy or cognitive therap* or psy-
chotherap*
or counsel* or sex therap* or patient educat* or behav* therapy or CBT or couple therap* or couple intervention or couple-based or
intimacy
enhancing or mindfulness or patient education or psychological techniques or psychosexual or psychotherapy or psycho-somatic or
Rational emotive
therap* or restoring intimacy or relaxation or relaxation therap* or relaxation training or psycho-social or Sensual, body image or sex-
counsel*
or sexual communication or sexual rehabilitation or sexuality or self-esteem or self concept or stress or psycho-education or sexual life
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reframing or coping skills or motivational counselling or anxiety management training or marital therap* or group therap* or focal
therap* or
psychodynamic therap* or supportive therap* or psychoanalyses or interpersonal therap* or individual therap* or problem solving or
emotional
support or hypnosis or bibliotherap* or sexual skills therap* or systematic desensitization or hypnotherapy* or radical emotive therap*
or
psychodynamic or psychoeducational)
S25 (MH “Cognitive Therapy”)
S24 (MH “Sexual Counseling”)
S23 (MH “Counseling+”)
S22 (MH “Psychotherapy+”)
S21 (MH “Psychological Techniques+”)
S20 (MH “Patient Education+”)
S19 (MH “St. John’s Wort”)
S18 (MH “Ginseng”)
S17 (MH “Ginkgo Biloba”)
S16 (MH “Vaginal Creams, Foams and Jellies”)
S15 (MH “Estrogens, Conjugated”)
S14 (MH “Estriol”)
S13 (vaginal dilator* or arginine or android or methyl testosterone or testosterone cream or vaginal lubricant or vaginal estradiol ring
or
vaginal estradiol ring or vaginal estrogen ring or vaginal oestrogen ring or topical estrogen creamor vaginal creamor estrogen replacement
of
ERT or estrogen replacement or aromatase inhibitors)
S12 (MH “Aromatase Inhibitors+”)
S11 (testosterone replacement or testosterone or venous constriction rings or vacuum device* or vacuum erect* or penile implant* or
penile
arterialisation or venous litigationor prosthesis implant* or vacuumconstrictiondevice or vacuum therapy* or vibrat* or vibrostimulation
or
electroejaculation or prolong ring*)
S10 (MH “Prostheses and Implants+”)
S9 (MH “Penile Prosthesis”)
S8 (MH “Testosterone+”)
S7 (alprostadil or androgel or Apomorphine or britaject or aromatase inhibitors or agonist of melancortin receptor or Adcirca or alpha
adrenoceptor agonist or alpha-2 adrenoceptor agonist or androgel or arginine or botox or botulinum toxin or bromocriptine or cialis
or
dopaminergic agents or caverject or clomipramine or cyproheptadine or clonidine or delquamine or edex or hormone therapy or
Isoxsuprine or
intracavernosal vasodilators or levitra or Lignocaine or l-arginine or lodenfil orMethitest ormethyl testosterone ormidodrin ormianserin
or
moclobemide or mirtazapine or mianserin or moclobemide or ortho-gynest or ovestin or papaverine or papaverine-phentolamine or
phentolamine or
parlodel or phentolamine or potassium channel openers or progestational agents or premarin or prempro or prostins or Prostaglandins
or
prostaglandin E1 or pentoxifylline or potassium channels or Phosphodiesterase Type 5 or PDE5i or penile suppository or reboxetine
or sildenafil
or tadalafil or tampovagan or topical or topical cream or vagifem or vaginal cream or vaginal lubricant or vaginal or viagra or vasomax
or Viagel
or vardenafil or vasodilator or virilon or vasoactive or staxyn or topical estrogen cream or trental or vasodilan or viridal or yohimbine or
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WH A T ’ S N E W
Last assessed as up-to-date: 8 September 2015.
Date Event Description
5 May 2015 New search has been performed We have updated this review to include the results of a
new search and added ’Risk of bias’ tables
20 February 2015 New citation required and conclusions have changed We have split the original review on interventions for
sexual dysfunction following treatments for cancer into
two reviews; the findings on interventions for sexual
dysfunction for men following cancer treatments will
now be reported in a separate review. We changed the
inclusion criteria to only include interventions specifi-
cally developed to treat sexual dysfunction; this led to
the exclusion of a study previously included because it
was a preventative study. We have added 11 new trials
and the conclusions have changed in the light of this
new evidence
H I S T O R Y
Protocol first published: Issue 4, 2005
Review first published: Issue 4, 2007
Date Event Description
8 February 2011 Amended Contact details updated.
24 September 2010 Amended Contact details updated.
9 November 2009 Amended Contact details updated.
13 May 2009 Amended Contact details updated.
30 October 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
In the 2015 update: BC carried out the searching and screening, reviewed documents, assessed quality and extracted data, analysed
data and first drafted the review. LJ advised on methods, screened, checked data extraction and commented on the draft. Input was
given to the protocol and final review. VV advised on statistics, checked the analysis and commented on the draft. AT contributed
to the original idea, advised on methods and commented on the draft. MK contributed to the original idea, advised on methods and
contributed to the draft. All authors read the final draft. BC is responsible for further updates.
D E C L A R A T I O N S O F I N T E R E S T
BC has no relevant conflicts of interest to declare. VV has no relevant conflicts of interest to declare. AT has no relevant conflicts of
interest to declare. MK and LJ are grant holders on a ongoing funded NIHR pilot randomised trial of a stepped care intervention for
women with sexual dysfunction after treatment for gynaecological cancer.
S O U R C E S O F S U P P O R T
Internal sources
• Marie Curie Cancer Care supported the review authors BC, LJ and VV, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This review is an update of an earlier review that included interventions for sexual dysfunction following treatments for cancer in both
women and men (Miles 2007). This review only includes interventions for treating sexual dysfunction following treatments for cancer
in women. All sections have been revised to reflect the patient group. The inclusion criteria for sexual dysfunction have been amended,
to make it clear what is eligible. More detail is also provided on outcomes of interest.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Intravaginal; Erectile Dysfunction [therapy]; Neoplasms [∗therapy]; Phosphodiesterase Inhibitors [therapeutic use];
Prostatic Neoplasms [therapy]; Psychotherapy; Randomized Controlled Trials as Topic; Sexual Dysfunction, Physiological [etiology;
∗therapy]; Sexual Dysfunctions, Psychological [∗therapy]; Uterine Cervical Neoplasms [therapy]; Vacuum; Vaginal Creams, Foams,
and Jellies [administration & dosage]
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MeSH check words
Adult; Female; Humans; Male
74Interventions for sexual dysfunction following treatments for cancer in women (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
